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CHAPTER I 
 
INTRODUCTION 
 
 Natural products have been an invaluable source of therapeutic agents1, 2.  
Of 1024 small molecule new chemical entities (NCEs) introduced between 1981 
and 2008, over half were natural products or natural product inspired synthetic 
derivatives.2  During this time period, natural products and their derivatives 
accounted for more than 68% of all anti-infectives (anti-bacterial, -fungal, 
-parasitic and -viral) and approximately 63% of all anticancer compounds.  An 
additional 225 natural product derived molecules are currently in clinical trials or 
preclinical development including 86 for cancer treatment and 40 for the 
treatment of infectious diseases.3, 4 While natural products are clearly vital for the 
treatment of human disease, the study of microbial ecosystems has been 
severely limited by the ability to cultivate less than 1% of the occupying 
microorganisms leaving a vast untapped resource for drug discovery.5-8   
 Over the past few years, sequencing technologies have advanced 
substantially, lowering the cost of genome sequencing.9 Total genome 
sequencing of a variety of actinomycetes (soil-dwelling bacteria) revealed large 
numbers of previously unidentified biosynthetic cassettes involved in the 
biosynthesis of natural products10-12.  In Streptomyces avermitilis alone, over 30 
putative gene clusters were identified.10, 11  In addition to revealing the untapped 
potential of actinomycetes for possible therapeutics, these genomic 
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advancements have allowed researchers to correlate previously identified 
bioactive natural products with their biosynthetic origins.  By correlating known 
natural products to their biosynthetic cassettes, researchers can tap into nature’s 
chemical repertoire by deconstructing the mechanisms required for natural 
product biosynthesis and harnessing that knowledge to generate novel 
therapeutics through synthetic biology.13 Herein, our investigations into 
understanding the biosynthesis of two previously uninvestigated peptide natural 
products from actinomycete species: K-26, a potent naturally produced 
phosphonate containing hypotensive agent, and anthramycin, an anti-cancer 
pyrrolobenzodiazepine, are described (Figure I-1).14, 15   
 
 
Figure I-1.  Chemical Structures of K-26 and Anthramycin K-26 is a unique phosphonate containing 
tripeptide capable of modulating ACE activity, while anthramycin in an anti-tumor, antibacterial 
pyrrolobenzodiazepine 
 
 
Case Study I: K-26 
 During the last several decades, both natural and synthetic phosphonate 
and phosphinate containing compounds have been used extensively in medicine 
and agriculture.16 (Table I-1)  These compounds are similar to phosphate esters 
and anhydrides, but are distinguished by carbon-phosphorus bonds replacing 
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one or more oxygen-phosphorus bonds (C-P in phosphonates and C-P-C in 
phosphinates).  The structural similarity of phosphonates and phosphinates to 
labile phosphate esters and carboxylic acids imparts their ability to act as 
substrate and transition state analogues of enzyme substrates, inhibiting enzyme 
catalysis.17   
 
                             Table I-1.  Bioactive Phosphonate Containing Compounds 
 
 
In 1959, the first naturally occurring phosphonate, 
2-aminoethylphosphonic acid (AEP), was identified.18  AEP is widely distributed 
in biological systems as a polar head group of membrane lipids.  Subsequently, 
additional phosphonylated macromolecules including exopolysaccharides and 
glycoproteins have been described19, 20.  Furthermore, a variety of phosphonate 
containing small molecules has been reported.  These include bialaphos, an 
herbicide; fosfomycin, an antibacterial; fosmidomycin, an anti-parasitic compound 
and K-26, a hypotensive agent.21 (Figure I-2) 
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Figure I-2. Phosphonate Natural Products. Representative examples of 
phosponate containing natural products.   
 
K-26, isolated from Astrosporangium hypotensionis (NRRL 12379), is a 
representative member of an uninvestigated class of phosphonate containing 
natural products which incorporate a phosphonic acid analogue of tyrosine.14  
NMR, mass spectrometry, degradation and synthetic investigations have 
demonstrated that K-26 is comprised of N-acetylated isoleucine, tyrosine and the 
non-proteinogenic amino acid (R)-1-amino-2-(4-hydroxyphenyl)ethylphosphonic 
acid (AHEP).14, 22   AHEP is shared among several related compounds produced 
by Streptosporangium and Actinomadura species.23, 24 (Figure I-3)   
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Figure I-3.  K-26 and analogues. Highlighted in red is a unique non-proteinogenic amino acid, AHEP. 
shared among a group of hypotensive tripeptides  
 
K-26 was initially discovered by bioactivity guided fractionation of A. 
hypotensionis culture extracts testing for inhibition of angiotensin converting 
enzyme (ACE).14  ACE is a zinc-dependent dipeptidyl carboxypeptidase which 
catalyzes the cleavage of carboxy-terminal dipeptides from numerous peptide 
substrates of the Renin-Angiotensin-Aldosterone system.25  All analogues of 
K-26 show some inhibition of ACE with K-26 possessing an IC50 value of 14.4 
nM, comparable to the widely prescribed anti-hypertension drug Captopril (7.7 
nM).26  Initial inhibition studies showed that K-26 is a non-competitive inhibitor of 
ACE with possible interactions between the phosphonate of AHEP and an active 
site zinc.14  Recent structure-activity relationship studies have revealed that the 
phosphonate moiety of K-26 is required for its inhibitory activity.26  K-26 was 
found to be 1500-fold more potent than its carboxylate congener.  Additionally, 
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the absolute configuration of AHEP and N-acetylation were found to play an 
important role in modulating ACE inhibitory activity. 
While it may seem unusual to isolate a compound capable of modulating 
mammalian ACE from a bacterial source, the presence of ACE homologues has 
been reported in non-vertebrates and unicellular microorganisms.27-46  Six ACE-
like enzymes have been identified in Drosophila melanogaster.28-46  Recent 
crystallography of one of these enzymes, AnCE, in complex with K-26 revealed 
that K-26 occupies two of the four available substrate binding pockets.27, 47  K-26 
binds within the S1 and S2 substrate binding sites with two of the phosphonic 
oxygen atoms coordinating to the active site Zn2+ ion, while the third oxygen 
hydrogen bonds with a histidine and tyrosine within the active site. (Figure I-4)  
Additional hydrogen bonds mediate and stabilize the binding of K-26 to AnCE.  
While the inhibition of AnCE by K-26 is lower (160 nM) than the inhibition of ACE 
(14.4 nM), this crystal structure provides insight into the mechanism of ACE 
inhibition by K-26 and the potential to develop new investigative tools and 
therapeutics.  It is important to note, however, that the role of K-26 in its 
environmental interactions, whether endogenous or exogenous, has not been 
established.  Despite the potent hypotensive activity of K-26 and related 
compounds, the biosynthetic pathway of K-26 has remained cryptic.   
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Figure I-4.  Binding Mechanism of K-26 in AnCE.  A recent crystal structure of K-26 bound to AnCE, an 
ACE-like protein produced by D. melanogaster, revealed interactions between the phosphonate of AHEP 
and the active site Zn2+ of AnCE. Used with permission.47 
 
Although completely characterized biosynthetic pathways of C-P bond 
containing natural products are rare, ongoing investigations have started to 
unravel the biosynthetic mysteries of several phosphonate natural products 
including AEP, fosfomycin and bialaphos.48-53  These investigations have 
revealed a unified biosynthetic route for the formation of the C-P bond.  The key 
enzyme involved in the generation of the phosphonate moiety in all previously 
studied C-P bond containing natural products is phosphonenolpyruvate mutase 
(PEP mutase).54-56  PEP mutase catalyzes the intramolecular rearrangement of 
phosphoenolpyruvate to phosphonopyruvate, which has been identified as a 
common biosynthetic antecedent of all PEP mutase derived phosphonate natural 
products.57 (Figure I-5) 
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Figure I-5. Biosynthetic Route to Phosphonate Moiety. All previously studied phosphonate natural 
products derive their phosphonate moiety from the conversion of phosphoenolpyruvate (PEP) to 
phosphonopyruvate (Ppyr) by PEP mutase. 
 
While the catalytic mechanism of PEP mutase has been widely studied, a 
unified mechanism has remained elusive.  There are two possible mechanisms 
consistent with the experimentally confirmed intramolecular phosphoryl transfer 
retaining absolute stereochemistry at the phosphorus.54, 57-59 (Figure I-6)  In 
mechanism I, the phosphoryl group is transferred to an active site residue of PEP 
mutase which is then attacked by the C(3) of the pyruvate enol intermediate.  
While in mechanism II, metaphosphate dissociates from PEP and is attacked by 
the C(3) of the pyruvate enol intermediate.  It is prosposed that in mechanism II, 
interactions with active site residues hold the metaphosphate in place, while 
rotation around the C1-C2 bond of the pyruvate enolate to allow attack of the 
C(3) onto the metaphosphate, which would account for the retention of 
stereochemistry at the phosphorus as well as the stereochemistry of the C1 
position of phosphonopyruvate. 
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Figure I-6.  Possible Mechanisms for PEP mutase.  There are two plausible mechanisms for PEP 
mutase.  In mechanism I, the phosphate of PEP is transferred to the active site of PEP mutase which is the 
attacked by the C(3) of the pyruvate enol intermediate.  In mechanism II, the phosphate dissociates from 
PEP mutase as metaphosphate which is then attacked by the C(3) of the pyruvate enol intermediate. 
 
Although PEP mutase is the biosynthetic route of all previously 
investigated C-P bond containing natural products, it is difficult to rationalize a 
possible biosynthetic pathway through phosphonopyruvate to generate AHEP.  
Comparison of AHEP to known C-P bond containing natural products makes it 
apparent that the mechanism of AHEP formation may be radically different than 
that of PEP mutase or an analogous enzyme.  Initial labeled precursor 
incorporation investigations into K-26 biosynthesis have revealed AHEP is a 
discrete intermediate of K-26 and is derived from tyrosine without the formation 
of a β-elimination intermediate.22, 60   
 
Case Study II: Anthramycin 
 Anthramycin is representative of a class of peptide natural products 
characterized by a 1,4-benzodiazepine ring system.15, 61  This class of 
compounds is composed of four pharmacophore groups: 1,4-benzodiazepine-2-
ones, 1,4-benzodiazepines-2,5-diones, dibenzodiazepinones and 
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pyrrolobenzodiazepines (PBDs). (Figure I-7)  Over 50 
1,4-benzodiazepine-2-ones are currently in clinically use for treatment of 
psychological diseases including insomnia, alcohol dependency and anxiety.61  
The most prominent member of this group is diazepam (Valium).  
1,4-benzodiazepene-2,5-ones have been tested as anticonvulsants, 
peptidomemetic inhibitors and herbicides.62-66  Within this group, only cyclopenin 
has been isolated from nature, identified as an intermediate to viridicatin, an 
inhibitor of HIV replication.67  The sole member of the dibenzodiazepinone group 
is the naturally produced TLN-4601 (ECO-4601) and is characterized by broad 
spectrum antitumor activity and is currently under phase I/II clinical trials.68, 69  
The final group, PBDs, includes both natural and synthetic compounds.  These 
compounds, including anthramycin, are potent alkylating agents reacting in the 
minor groove of DNA, imparting both antibacterial and antitumor activities.70-74 
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Figure I-7.  Classes of 1,4-benzodiazepine.  Representative members of the 1,4-benzodiazepine family of 
compounds.  The core 1,4-benzodiazepine structure is highlighted in red. 
  
PBDs are structurally defined by a tricyclic ring system consisting of an 
aromatic A-ring, a seven-membered diazepine B-ring and a hydropyrrolidine 
C-ring.75  Chemical diversity of PBDs is introduced by varied substitution patterns 
of the A-ring and unsaturation at the C2-C3 bond and/or an exocyclic moiety at 
the C2 position of the C-ring (Figure I-8).  Currently, 19 natural PBDs have been 
isolated from bacterial cultures, including anthramycin.  While 16 natural PBDs 
show moderate antimicrobial properties, their antitumor activities are the most 
intriguing.15   
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Figure I-8.  Examples of Bacterial Pyrrolobenzodiazepines. Chemical diversity of PBDs is introduced by 
varied substitution patterns of the A-ring and unsaturation at the C2-C3 bond and/or an exocyclic moiety at 
the C2 position of the C-ring.  Inactive PDBs have a carbonyl at the C11 of the B-ring, exemplified here by 
RK1441B 
 
Anthramycin has shown broad spectrum antitumor activity in vitro 
including against HeLa, Sarcoma 180, Walker 256 carcinosarcoma and leukemia 
P388 cell lines.76  In initial human studies, of 219 patients with unresponsive 
tumors, including lymphomas and sarcomas, approximately half saw a significant 
decrease in tumor size.76  At the concentrations used, 0.02 mg/kg, no side effects 
were observed.  However at concentrations between 0.1 and 0.5 mg/kg, 
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cardiotoxicity was observed in rats.77  Structure-activity relationship studies 
suggest that the C9 hydroxyl of the A-ring may be the source of these cardiotoxic 
side effects and synthetic analogues have been created reducing this activity.73, 
74, 77, 78 
Initial experiments investigating the mechanism of inhibition of replication 
and transcription in cells by anthramycin revealed that anthramycin showed 
preferred binding to double stranded DNA over single stranded DNA and RNA.79  
Co-purification of anthramycin with double stranded DNA indicated covalent 
modification of DNA by anthramycin, while experiments with single stranded 
polydG suggested that guanine may be the reactive DNA residue.80, 81  Structural 
studies including NMR and crystallography illuminated the role of a covalent 
bond between the C11 position of the B-ring and an exocyclic amino group of a 
guanine base within the DNA binding sequence74, 82-88.  Anthramycin, sibiromycin 
and tomaymycin alkylate DNA in a site-specific manner preferring the reactive 
guanine to be situated between two purine nucleobases rather than 
pyrimidines.85, 89, 90  In terms of DNA affinity, the binding order is as follows: 
sibiromycin > anthramycin > tomaymycin > DC-81 > neothramycin.61, 72  The 
conformational flexibility of the PBD and degree of right-handed twist may be 
responsible for the differences in binding affinity.91  
 Currently, there are two plausible mechanisms for the bioactivity of PBDs 
consistent with experimental data.92, 93  In solution, PBDs can exist in three 
interconverting forms: the imine form, the carbinolamine form and in methanol, 
the carbinolamine methyl ether form.  In mechanism I, a direct SN2 reaction of the 
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guanine amine on the carbinolamine carbon with water elimination leads to 
alkylation.  In mechanism II, alkylation results from a direct reaction of the 
guanine amine with the imine form.  (Figure I-9) 
 
 
Figure I-9.  Proposed Mechanism for PDB Bioactivity.  Research strongly suggests that DNA alkylation 
occurs from a direction reaction of a guanine amine within the minor groove of B-DNA with the imine form of 
PBDs. 
 
Mechanism II is strongly supported by the formation of two diastereomers 
of tomaymycin-DNA adducts (11S, 11aS and11R, 11aS) in a proportion different 
than while free in solution and increased reactivity of PBDs when electron-
donating substitutions are present on the A-ring.82, 87, 94, 95  The S configuration at 
the C11a position allows the PBD scaffold to adopt a right-handed twist permits 
binding within the minor groove of B-DNA.  While there are four possible binding 
configurations of PBDs (two for each diasteromer: 5’ to 3’ or 3’ to 5’ orientations), 
anthramycin mainly binds with the C-ring on the 5’-end of the modified DNA 
strand resulting only in the 11S, 11aS adduct, likely due to the 35o twist of 
anthramycin causing steric clashing in the other three binding configurations.87, 96 
(Figure I-10) Hydrogen bonding of the A-ring substituents and the C-ring 
acrylamide tail may increase the stability of this adduct.  
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Figure I-10 Anthramycin Bound in the Minor Groove of DNA. The 
duplex is represented in CPK in (A) and sticks in (B).  Used with 
permission.15 
 
 
Despite the potent biological activities of PBDs, little is known about their 
biosynthesis.  The structural similarities of PBDs indicate that they may be 
derived from common precursors through parallel biosynthetic pathways.  
Labeled precursor feeding studies with the producers of anthramycin, sibiromycin 
and tomaymycin by Hurley and coworkers identified the amino acid precursors of 
these PBDs97-99. (Figure I-11) The anthrinilate A-ring of all three PBDs is derived 
from L-tryptophan with retention of the indole nitrogen, while the dehydroproline 
C-ring is derived from L-tyrosine.  Labeled L-methionine was incorporated into the 
4-position of the A-ring and the C-1 position of the exocyclic side chain of the 
C-ring.  Glucose provides the precursor of the sugar incorporated into 
sibiromycin.   
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Figure I-11.  Precursor Incorporation Studies with Bacterial PBDs.  Hurley and coworkers established 
the amino acid precursors to bacterial PDBs.  The A-ring is derived from tryptophan and the B-ring is derived 
from tyrosine, while methylations are methionine dependent. 
  
Based on the structural similarity of the A-ring of these PBDs to anthranilic 
acid, a primary metabolite, additional investigations with 14C-labeled anthranilic 
acid were performed.97, 98, 100, 101  However, efficient incorporation of anthranilic 
acid was only detected in tomaymycin.  The A-ring of anthramycin and 
sibiromycin share a similar core: 4-methyl-3-hydroxyanthranilic acid (MHA).  
However, feeding studies with 3-hydroxy-4-methyl-[2-14C]-anthranilic acid 
resulted in incorporation solely into sibiromycin.  Lack of labeled MHA 
incorporation into anthramycin may be due to the impermeability of Streptomyces 
refuineus to anthranilate analogues.  The incorporation of L-tryptophan and 
anthranilic acid derivatives into tomaymycin and sibiromycin suggest that the A-
ring of PBDs may be from oxidative ring opening of L-tryptophan to L-kynurenine 
followed by the primary kynurenine pathway to give the anthranilic acid 
derivatives. (Scheme I-1)  Competition experiments identified four possible 
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intermediates: L-kynurenine, 3-hydroxykynurenine, 3-hydroxy-4-
methylkynurenine and MHA for the biosynthesis of the sibiromycin A-ring 
supporting the role of the kynurenine pathway in the formation of the A-ring. 
 
 
Scheme I-1.  Proposed MHA Biosynthetic Pathway.  Hurley et al proposed the derivation 
of MHA from the primary metabolic kynurenine pathway based on radiolabeled precursor 
incorporation studies. 
  
The biosynthesis of the dehydroproline C-ring of anthramycin, sibiromycin 
and tomaymycin may proceed through a pathway similar to lincomycin 
biosynthesis in Streptomyces lincolnensis.102, 103  In order to form the C-ring from 
L-tyrosine, an oxidative cleavage was proposed.  The biotransformation of 
L-tyrosine to the five membered proline ring structure would first proceed through 
conversion of L-3,4-dihydroxyphenylalanine (L-DOPA) followed by subsequent 
oxidative cleavage.  Feeding experiments performed by Hurley and coworkers 
support a route in which the pi-bond between C5 and C6 in tyrosine is broken 
prior to the formation of the five-membered ring.  After pentacyclic ring closing, 
insertion of the exocyclic moiety would occur.  (Scheme I-2) 
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Characterization of a strain of S. lincolnensis unable to produce lincomycin 
led to the isolation and identification of 4-propylidene-3,4-dihydropyrrole-2-
carboxylic acid, a proposed intermediate in the biosynthetic pathway of 
lincomycin.103  Genomic analysis of the lincomycin gene cluster revealed that this 
intermediate is due to the inability of this strain to synthesize a cofactor required 
for an F450 reductase, a participant in lincomycin biosynthesis.104  Limited 
functional assignment could be generated for other genes within this biosynthetic 
cassette due to little to no similarity to characterized proteins within the Protein 
Data Base (PDB).   
Currently, only the activities of two enzymes within this pathway have 
been assigned.105, 106  LmbB1 contains the catechol-2,3-dioxygenase signature 
sequence Hx7FYx2DPxGx3E and catalyzes the conversion of L-DOPA to 
4-(3-carboxy-3-oxopropenyl)2,3-dihydropyrrole-2-carboxylic acid through a 
transient intermediate with an absorbance of 378nm.107  Structural studies 
support the enzymatic formation of a semialdehyde followed by non-enzymatic 
cyclization to the α-hydroxyacid.  The activity of LmbB2 was indirectly assigned 
by observing to 4-(3-carboxy-3-oxopropenyl)2,3-dihydropyrrole-2-carboxylic acid 
only in cells transformed with a plasmid containing both lmbB1 and lmbB2.108  
Based on the structural similarity of PDBs to lincomycin, the C-ring of the PBDs 
may follow a similar biosynthetic route. 
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Scheme I-2.  Proposed Dehydroproline Acrylamine Biosynthesis.  Precursor incorporation studies 
identified tyrosine as the amino acid precursor to the dehydroproline acrylamide hemisphere of anthramycin.  
Subsequent work with the analogous pathway in lincomycin confirmed the first two steps in the proposed 
biosynthesis. 
 
Peptide Bond Biosynthesis 
 K-26 and anthramycin are unified by their peptidic nature and the 
incorporation of non-proteinogenic amino acids.  Currently, there are three known 
paradigms for peptide biosynthesis: ribosomal, non-ribosomal and ligase-based. 
 
Non-ribosomal Peptide Natural Product Biosynthesis 
 As the most prevalent biosynthetic paradigm for peptide natural products, 
non-ribosomal peptide synthetases (NRPS) have been shown to incorporate 
some 500 different monomers including the 20 proteinogenic amino acids, 
non-proteinogenic amino acids, fatty acids and α-hydroxy acids.109, 110  The 
structural diversity imparted by the precursor assortment may contribute 
substantially to the broad clinical applications of non-ribosomal peptide natural 
products.  Usually, the biosynthetic machinery of non-ribosomal peptides is 
clustered together in a large cassette.  In addition to the genes encoding NRPSs, 
genes for amino acid biosynthesis, glycosylation, acetylation, transport and 
resistance may be found within the biosynthetic cassette.110 NRPS are very large 
(>100 kD) proteins comprised of distinct modules, each responsible for the 
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incorporation of one discrete monomer into the final peptide.111-114  Each module 
minimally consists of at least three domains: an adenylation (A)-domain, a 
thiolation (T)-domain and a condensation (C)-domain.110, 111   
 The A-domain selects the cognate amino acid and catalyzes the formation 
of a reactive aminoacyl adenylate intermediate utilizing ATP and releasing 
pyrophosphate.115  (Figure I-12)  Using biochemical, structural and phylogenic 
information, the amino acids of the A-domain involved in amino acid substrate 
binding were revealed.116, 117  The crystal structure of PheA identified the amino 
acids involved in L-phenylalanine binding.  This 8- to 10- amino acid specificity-
conferring code can be extracted from primary sequence data of A-domains by 
sequence alignment to PheA.  It is possible to predict the substrate specificity of 
a given A-domain based on identity of the specificity-conferring code to 
previously characterized A-domains.118 
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Figure I-12.  A-domain Reactivity and Specificity. Top: An NRPS A-domain catalyzes the formation of an 
aminoacyl adenylate by utilizing ATP and subsequently reacts the aminoacyl adenylate with the free thiol of 
the phosphopantetheinyl moiety of the T-domain.  Middle:  Based on the crystal structure of PheA, 10 amino 
acids were identified involved in substrate discrimination.  These amino acids confer a substrate specificity 
code (Lysine 517 not shown).  Bottom Left:  Representative examples A-domains and their respective 
specificity code.  Bottom Right:  A schematic of substrate binding within the amino acid binding pocket of 
PheA. 
 
After formation of the reactive aminoacyl adenylate intermediate, the 
A-domain tethers the amino acid to a post-translationally modified T-domain by 
thioesterification.119, 120 (Figure I-13)  All T-domains must be post-translationally 
modified prior to fulfilling their role as transport proteins during peptide bond 
formation.  Formation of the active holo-T-domain requires transfer of the 
4’phosphopantetheinylate of coenzyme A (CoA) to an active site serine residue 
of the apo-T-domain by a phosphopantetheinyl transferase (PPTase).  The 
activated aminoacyl adenylate reacts with the terminating sulfhydryl group of the 
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phosphopantetheinyl moiety resulting in an energy-rich thioester primed for 
condensation into the growing peptide product.   
 
 
Figure I-13.  The Role of the T-Domain in NRPS Systems.  After post-translational modification of an 
active site serine residue with phosphopantethiene, the A-domain activates the cognate amino acid 
substrate as the aminoacyl adenylate and catalyzes the thioesterification of the phosphopantetheinyl moiety 
with the aminoacyl adenylate to give the tethered amino acid primed for condensation into the peptide. 
 
Peptide bond formation is catalyzed by the C-domain by promoting 
nucleophilic attack of the amino group of the activated amino acid bound to the 
downstream (of the C-domain) module onto the acyl group of the amino acid 
tethered to the upstream module.121, 122 (Figure I-14) Based on the recent crystal 
structure of a T-C didomain from tyrocidine biosynthesis, the C-domain has a 
V-shaped architecture, possessing sites for both the upstream and downsteam 
T-domain tethered amino acids.123, 124  Additional substrate specificity for the 
nucleophilic amino acid substrate is imparted within the C-domain by the 
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structure of the respective binding pocket preventing incorporation of an incorrect 
amino acid into the peptide. 
 
Figure I-14.  C-Domain Reaction Mechanism.  Two T-domains of neighboring modules are loaded with 
their cognate amino acid.  The electrophile amino acid enters the acceptor site (1) and the nucleophile 
amino acid enters the donor site (2) of the C-domain.  After peptide bond formation, the resulting dipeptide 
can now act as the electrophile in the active site of the subsequent C-domain. 
 
In most NRPS, the peptide is released by the activity of a thioesterase 
(Te)-domain.125, 126  The growing peptide chain is handed from one module to the 
next until it reaches the last T-domain on the final module.  Release of the final 
peptide is catalyzed by a two-step process through an acyl-O-Te-enzyme 
intermediate that is attacked by either an internal nucleophile on the peptide or 
water, resulting in either a cyclic or linear peptide, respectively.127, 128  
Alternatively, a reductase domain can release the peptide with a terminal 
aldehyde or alcohol. 
Additional structural diversity is incorporated into non-ribosomal peptides 
by tailoring domains.129  These domains fall into two categories: integral parts of 
the NRPS acting in cis on the growing peptide or distinct enzymes acting in trans.  
These domains include cyclization (Cy)-domains, which form thiazoline and 
oxazoline rings from cysteine, serine and threonine residues; oxidation 
(Ox)-domains, responsible for oxidation of the thiazoline and oxadoline rings to 
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thiazoles and oxazoles, respectively; epimerization (E)-domains epimerize an L 
amino acid to a D amino acid and methyltransferase (MT)-domains insert a 
methyl group on an amino acid substrate using S-adenosyl methionine as the 
methyl donor. 
Initial investigations into the biosynthesis of non-ribosomal peptides 
identified a direct link between the order of the modules of the NRPS, including 
the domains within those modules, and the incorporation of the amino acid into 
the growing peptide.112, 130-132  This hierarchy of reactions was coined the 
co-linearity rule.  (Figure I-15) For example, the cyclic lipopeptide surfactin 
follows this biosynthetic route.133 A total of 24 domains are organized in seven 
modules over three NRPS that act linearly, starting at module 1 and ending at 
module 7.  However, as more gene clusters were identified, deviations from the 
co-linearity rule were identified.  Two types of deviations are iterative, exemplified 
by gramicidin S, and non-linear, exemplified by vibriobactin.112, 134  In gramicidin 
S biosynthesis, a pentapeptide monomer is formed and stalled on the final 
module.127, 135 The regenerated NRPS then engages in a second round of 
synthesis and is released by a head-to-tail cyclization to give the final product.  In 
non-linear biosynthesis of an NRPS, the domains are arranged non-linearly, 
often missing expected domains, repeat use of single domains or include inactive 
domains.112 
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Figure I-15.  NRPS Biosynthetic Strategies. Top:  In linear NRPSs, synthesis proceeds from module 1 to 
module 7 until the final product is released by the Te-domain of the last module.  Middle:  In iterative 
NRPSs, the modules of the NRPS are used multiple times in succession and the Te-domain catalyzes the 
dimerization of the two peptides to gives a homodimeric product.  Bottom:  Non-linear NRPSs, do not follow 
the co-linearity rule.  
 
Ribosomal Peptide Natural Product Biosynthesis 
 While NRPSs are the most common biosynthetic route for peptide natural 
products, in recent years, a growing number of ribosomally encoded cyclic 
peptides have been identified.136-147 Briefly, three basic enzymes are required for 
ribosomal production of peptides.  The aminoacyl-tRNA synthetase first selects 
the cognate amino acid and loads it onto either the 2’ or 3’ hydroxyl group of the 
corresponding tRNA, depending on whether the synthetase is classified as a 
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Class I or II, respectively.148, 149  The ribosome is the catalytic machine 
responsible for generating the amino acid sequence of a peptide, based on the 
sequence of the bound mRNA.150 The ribosome selects the correct aminoacyl-
tRNA, with the help of elongation factor (EF)-Tu.  The aminoacyl-tRNA, EF-Tu 
and GTP enter the acceptor (A)-site of the ribosome.  The large ribosomal 
subunit stimulates hydrolysis of GTP committing the aminoacyl-tRNA to peptide 
bond formation, releasing EF-Tu.  The amino acid-tRNA complex is bound via 
codon-anticodon recognition to the ribosome. Peptide bond formation occurs 
through nucleophilic attack of the amino group of the aminoacyl-tRNA in the 
A-site on the carbonyl of the aminoacyl-tRNA, with the attached peptide, in the 
peptidyl (P)-site.  The tRNA with the attached polypeptide is now pushed from 
the A-site to the P-site, while the unloaded tRNA in the P-site shifts to the exit 
(E)-site.  Subsequent cycles elongate the polypeptide.   
 Unlike non-ribosomal peptides, ribosomal peptides are limited by the 20 
proteinogenic amino acids.  However, extensive posttranslational modification of 
the precursor peptide imparts structural diversity to the peptide scaffold.  For a 
majority of ribosomal peptide natural products, a series of genes encode a 
precursor peptide containing an N-terminal leader peptide and a C-terminal core 
peptide that is processed into the final compound.151 (Figure I-16) Variably, the 
N-terminus of the leader peptide may be appended with a signal peptide 
governing subcellular localization and/or a recognition sequence may be 
attached to the C-terminal end of the core peptide.  After post-translational 
modification, the precursor peptide is usually cleaved by at least one protease 
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freeing the core peptide.  The gene cluster containing the precursor peptide also 
encompasses genes encoding modifying enzymes, resistance and secretion. 
 
Figure I-16.  General Ribosomal Peptide Biosynthesis.  The precursor peptide usually consists of an 
N-terminal leader peptide and a C-terminal core peptide.  A signal peptide and/or recognition sequence may 
be appended to the main peptide structure.  The precursor peptide is ribosomally synthesized and post-
translationally modified to the active compounds. Used with permission151 
 
Several roles have been proposed for the N-terminal leader peptide, 
though none have been completely substantiated experimentally.151  In fact, the 
role of the leader peptide may differ between families of ribosomal peptides or 
even within an individual class.  Most often, it is proposed that the leader peptide 
plays a role in signaling secretion of the core peptide; however, most of the 
leader peptides in these gene clusters display no homology to proteins involved 
in bacterial secretion pathways.  Additional proposed roles for the leader peptide 
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include acting as a recognition motif for post-translational modification enzymes 
including perhaps acting as chaperones for enzymes assisting in folding of the 
precursor peptide and stabilizing the peptide against degradation and premature 
activation of its biological function.  Supporting the role of the leader peptide as a 
preventative to premature activation, the protease involved in cleaving the 
precursor peptide resides on the outside of the producing cell. 
 Despite the variability of the precursor peptides, both between and within 
classes, they remain substrates for post-translational modification.  Both the side 
chains and main peptide chain can undergo post-translational modifications.  
Herein, I provide an overview of several families of ribosomal peptide natural 
products produced by bacteria and the modifications of those peptides as 
representative examples of their biosynthesis.  These four families were chosen 
based on their prevalence in nature and the inclusion of post-translational 
modifications within their structure.  
 
Lantibiotics 
Lantibiotics are divided into two classes based on their leader peptide 
sequences and biosynthetic enzymes.  Class I lantibiotics have leader peptides 
approximately 25 amino acids in length, rich in aspartic acid residues.152  In this 
class, the leader peptide greatly reduces the antimicrobial activities of the core 
peptide and appears to be involved in the recruitment of enzymes for peptide 
modification and excretion.153, 154  Class II lantibiotics have leader peptides rich in 
aspartate and glutamate residues, contain an ELXXBX motif (where B = V, L or I) 
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and usually end in two glycine residues.155  The double glycine motif is required 
for proteolytic cleavage of the precursor peptide, while the leader peptide itself 
may be involved in secretion and guidance of additional biosynthetic enzymes 
involved in producing the final natural products.156-158 A total of 15 
post-translational modifications have been documented within the lantibiotic 
family.159 (Figure I-17) Structurally, the lantibiotic family of ribosomal peptide 
natural products is distinguished by thioether crosslinks introduced by the 
dehydration of serine and threonine to dehydroalanine and dehydrobutyrine, 
respectively, followed by addition of the thiol of cysteine.   
 
 
Figure I-17.  Post-translational Modifications Found in Lantibiotics. A total of 15 post-translational 
modifications have been identified in the lantibiotics family.  This family of ribosomal peptide natural products 
is distinguished by the incorporation of a variety of thioether crosslinks. 
 
Microcins 
Microcins are small, structurally diverse peptides produced by 
enterobacteria.160  As opposed to the lantibiotics, only a few different types of 
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post-translational modifications have been reported for microcins.161-164  One 
class of peptides within this family is exemplified by microcin B17, which contains 
oxazole and thiazole heterocycles.161 (Figure I-18) The formation of these 
heterocycles requires three proteins including a cyclodehydratase, which 
generates the oxazoline and thiazoline structures from Gly-Ser and Gly-Cys 
sequences; a flavin-dependent dehydrogenase, responsible for oxidizing these 
intermediates to the oxazole and thiazole structures and a scaffolding protein, 
required for catalysis.165  The leader peptide for these types of microcins has 
been shown to interact with the scaffolding proteins and reduce the antimicrobial 
activity of the core peptide.166, 167 
 
Figure I-18.  Microcin Ribosomal Peptides.  Two classes found within the Microcin family of peptide 
natural products are  the thiazole and oxazole containing peptides and the lasso peptides.  Used with 
permission.151 
  
Another class of peptides within the microcin family is the lasso peptides, 
exemplified by microcin J25.162-164 (Figure I-18) In these peptides, the 
distinguishing feature is a lactam bond.  The N-terminal amino group reacts with 
the carboxylate side chain of an aspartate or glutamate residue at position 8, 
essentially trapping the C-terminus of the peptide chain threaded through the 
ring.  The leader peptide of microcin J25 has been shown to be required for the 
 31 
 
recruitment of two enzymes involved in post-translational modification of the core 
peptide.146, 168  One protein catalyzes the adenylation of the aspartate/glutamate 
carboxylate at position 8, while a second cleaves off the leader peptide and 
installs the new lactam bond. 
 
Cyanobactins 
 Produced by diverse cyanobacteria, over 100 unique cyclic peptides 
belong to the cyanobactin family, including the patellamides.146 (Figure I-19) 
Members of this family of ribosomal peptide natural products share similar 
structural features, like oxazoles and thiazoles, as well as, similar biosynthetic 
origins.  Two enzymes, a cyclodehydratase and a bifunctional enzyme with an 
oxidase domain, are required for the cyclization of serine, threonine and 
cysteine.169  Proteolytic cleavage of the precursor peptide releases the core 
peptide which is then cyclized to give the final product. 
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Figure I-19.  Proposed Biosynthesis of Patellamides A and C.  Cyanbactins differ from other types of 
ribosomal peptide natural products by incorporating two core peptides in the precursor peptide. 
 
Interestingly, most cyanobactin precursor peptides consist of a leader 
peptide, whose activities have not been substantiated in vitro, and two highly 
variable core peptides flanked between recognition sequences responsible for 
directing post-translational modification of the core peptides.146  The N-terminal 
region flanking the first core peptide typically contains a conserved 
G(L/V)E(A/P)S sequence, while the C-terminal region contains a conserved 
AYDG(E) sequence, which act as recognition sequences for the excision and 
cyclization of the core peptides.169   
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Thiopeptides 
 Thiopeptides are another large class of ribosomally encoded natural 
products containing a string of thiazoles/thiazolines which are conjoined by a six-
member heterocyclic ring.136, 139, 142, 144, 170 (Figure I-20)  This heterocycle can be 
a pyridine, hydroxypyridine or a dehydropiperadine.  Common modifications 
within the thiopeptide family include dehydrations of threonine and serine, 
thiazole and thiazoline formation and proposed cyclization of two 
dehydroalanines to form the six-membered ring structure. 
 
 
Figure I-20.  Biosynthesis of Thiostrepton.  Thiostrepton is initially encoded as the precursor peptide 
TsrH.  Subsequent post-translational modifications install the heterocycle rings and dehydrated amino acid.  
This conformationally restrained peptide is further modified to give the characteristic central hexacycle of 
thiopeptides.  Although represented in a particular order, the timing of the biosynthetic steps is not known. 
Used with permission.151 
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Ligase-based Peptide Biosynthesis 
While non-ribsomal and ribosomal natural products make up the majority 
of peptide natural products, increasing examples of ligase-based biosyntheses 
have been reported in the literature, including non-ribosomal independent 
pathways, aSerRS homologues amino acid:[carrier protein] ligases and the 
recently identified ATP-independent strategy.171-175  The biosynthesis of the 
dapdiamide antibiotics provides one example of the role of ATP-dependent 
ligases in peptide natural product biosynthesis.172 (Figure I-21) ATP-dependent 
ligases are soluble enzymes that couple amino acid monomers to the growing 
peptide chain.  There are two types of ATP-dependent ligases involved in 
dapdiamide biosynthesis.  DdaG activates fumarate, as the aminoacyl adenylate 
using ATP and releasing pyrophosphate, and forms the first peptide bond 
between fumarate and 2,3-diaminopropionate (DAP) to create the 
Nβ-fumaroyl-DAP dipeptide intermediate.  Activity similar to DdaG occurs during 
the ATP-dependent biosynthesis of the siderophore ferrioxamine E by the non-
ribosomal synthetase independent pathway.173, 174  After amination of 
Nβ-fumaroyl-DAP to Nβ-fumaramoyl-DAP, DdaF activates the dipeptide as the 
acyl phosphate by using ATP and releasing ADP, similar to the ligases involved 
in glutathione and bacterial cell wall pentapeptide biosynthesis.176, 177 
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Figure I-21.  Dapdiamide Biosynthesis.  The biosynthesis of the dapdiamides requires two ATP-
dependent ligases, DdaG, which employs an aminoacyl adenylate and DdaF, which utilizes an 
aminoacylphosphate, to activate amino acids for peptide bond formation. 
 
More recently, two other biosynthetic pathways for peptides have been 
identified.  Homologues to serine tRNA synthetase (aSerRS) have been 
identified in a variety of bacterial species including Alpha- and 
Betaproteobacteria, Clostridium, Bacillus and Streptomyces species.175  While 
showing homology to serine tRNA synthetases, these proteins, exemplified by 
two homologues from Bradyrhizobium japonicum (BII0957 and BII6282) and one 
homologue from Agrobacterium tumefaciens (Atu2573), activate amino acids in 
the same manner as tRNA synthetases, but do not load amino acids onto tRNA.  
As the genes for these proteins are often near genes for small hypothetical 
proteins with a 4’phosphopantetheine attachment site, it was proposed that 
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aSerRS may be capable of loading these T-domain-like proteins called carrier 
proteins (CP).  The three aSerRS (BII0957, BII6282 and Atu2573) were shown to 
tether alanine or glycine to these neighboring CPs; however, the peptide product 
of this route of biosynthesis has not been identified.  
Unlike the other ligase-based biosynthetic pathways, another recently 
identified route for peptide bond formation is ATP-independent.171  
Capuramycins, produced by Streptomyces sp SANK 62799 and Streptomyces 
griseus SANK 60196, are nucleotide containing peptide natural products. (Figure 
I-22) The structure of the capuramycins consists of three distinct portions: a 
5’-C-carbamoyl-uridine, an unsaturated hexuronic acid and an aminocaprolactam 
ring.  The gene cluster for capuramycin A-503083 (A and B) contains two NRPS 
genes believed to be involved in the biosynthesis of the L-aminocaprolactam ring, 
while, two additional genes are required for the installation of the 
aminocaprolactam ring into the final capuramycin structure.  CapS activates the 
carboxylic acid of the hexuronic acid-carbamoyl uridine complex by S-adenosyl 
methionine-dependent methylation.  CapW is responsible for the condensation of 
the hexuronic acid-carbamoyl uridine complex with the amino caprolactam ring. 
 
 
Figure I-22.  ATP-independent Peptide Bond Formation.  The biosynthetic pathway of the capuramycins 
includes a unique method for peptide bond formation.  CapS installs a methyl on the free carboxylate of the 
hexuronic acid-carbamoyl uridine complex.  This activated complex is then condensed with 
L-aminocaprolactam by CapW, releasing methanol and creating the final peptide. 
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Biosynthetic Hypotheses for K-26 and Anthramycin 
 Based on the chemical structures, we propose both K-26 and anthramycin 
are produced by NRPS:   
K-26 
The intermediacy of AHEP suggests that K-26 may be biosynthesized by 
the NRPS paradigm.  In this case, L-isoleucine, L-tyrosine and AHEP would be 
activated by individual A-domains, loaded onto the corresponding T-domains and 
peptide bond formation would be catalyzed by the C-domain resulting in the 
formation of des-acetyl-K-26 (dK-26). (Figure I-23) Then either on the final 
T-domain or after release of the peptide by the Te-domain, N-acetylation would 
occur resulting in formation of K-26.  Our proposed gene cluster would consist of 
an N-acetyltransferase, NRPS with a domain string of A-T-C-A-T-C-A-T-Te and 
hypothetical proteins of unknown function responsible for AHEP biosynthesis.   
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Figure I-23.  Proposed Peptide Bond Formation in K-26.  Based on the non-proteinogenic nature of 
AHEP, the most logical biosynthetic route for K-26 formation is via the NRPS paradigm.  In this case, the 
discrete precursors would be activated and loaded onto individual T-domains by the corresponding A-
domains.  Peptide bond formation would be catalyzed by the C-domains and the peptide would be released 
by a thioesterase.  N-acetylation could occur prior to peptide bond formation or afterward as depicted. 
 
Anthramycin 
   Based on the non-proteinogenic nature of the two amino acids proposed 
in the formation anthramycin, evidenced by the aforementioned isotopic 
incorporation experiments, we propose an NRPS based biosynthetic hypothesis 
with a domain string of A-T-C-A-T-Re. (Figure I-24) The first A-domain of the 
NRPS would activate either 3-hydroxyanthranilic acid (HA) or MHA and the 
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second A-domain would activate the dehydroproline acrylamide hemisphere for 
loading on to their respective T-domains.  A specialized reductase domain would 
provide the final cyclization to form the final benzodiazepine ring of anthramycin. 
 
 
Figure I-24.  Proposed Peptide Bond Formation in Anthramycin.  Based on the non-proteinogenic 
nature of the two proposed precursors of anthramycin, peptide bond formation by an NRPS is the most 
logical hypothesis.  In this case, the discrete amino acid precursors would be activated by individual A-
domains and loaded onto the corresponding T-domains.  The lone C-domain would catalyze peptide bond 
formation and a unique reductase domain would release anthramycin from the megasynthetase by installing 
the benzodiazepine ring. 
 
Dissertation Goals 
 Within this dissertation the first biosynthetic investigations of two natural 
product classes are described.   
Chapter II describes the development of the mass-based pyrophosphate 
exchange assay for characterization of the proteins involved in the biosynthesis 
of K-26 and anthramycin. 
Chapter III describes the biosynthetic investigations of K-26, including our 
attempts at isolating the peptide bond forming machinery.  This work is currently 
the only research being performed investigating this unique phosphonate 
containing natural product. 
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Chapter IV describes the biosynthetic investigation of anthramycin, 
including the first biochemical characterization of the enzymes involved in 
anthramycin biosynthesis. The work described herein is the first identification and 
characterization of a PBD gene cluster.  It is important to note that after 
publication of our investigations into the biosynthesis of anthramycin, biosynthetic 
investigations of both sibiromycin and tomaymycin were published by the 
Gerratana laboratory. 
Chapter V describes the possible future biosynthetic investigations of 
K-26 and anthramycin. 
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CHAPTER II 
 
γ-18O4-ATP PYROPHOSPHATE EXCHANGE ASSAY 
Introduction 
Most peptide natural products, especially those containing 
non-proteinogenic amino acids, such as those proposed in the biosynthesis of 
K-26 (AHEP) and anthramycin (MHA and (E)-4-(3-amino-3-oxoprop-1-enyl)-2,3-
dihydro-1H-pyrrole-2-carboxylic acid), are formed via the NRPS paradigm.1 In 
order to investigate the biosynthesis of the peptide natural products K-26 and 
anthramycin, we required an assay to test for amino acid activation necessary for 
peptide bond formation in NRPS based peptide biosynthesis.  First developed by 
Lee and Lipmann in 1975, the pyrophosphate exchange assay takes advantage 
of the non-catalytic reversible nature of isolated synthetases (both tRNA 
synthetases and NRPS A-domains) to reveal the substate specificity of the 
synthetase of interest.2  These isolated synthetases perform half reactions of 
cognate amino acid with ATP creating tightly bound aminoacyl adenylates 
releasing pyrophosphate.  Subsequent amino acid esterification to the respective 
tRNA or T-domain prepares the amino acid substrate for peptide bond formation 
(Figure II-1). 
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Figure II-1.  Role of A-domains in NRPS.  NRPS A-domains catalyze the reversible 
formation of aminoacyl adenylates for subsequent thiolation reactions to tether the amino 
acid on T-domains.  The reversible nature of aminoacyl adenylate formation can be 
exploited to identify the amino acid substrate of the A-domain. 
 
Classically, pyrophosphate exchange activity is assayed using the 
ATP-32PPi isotope exchange assay where the synthetase of interest is incubated 
with an excess of ATP, amino acid and 32PPi and the reversible back-exchange 
of labeled 32PPi into ATP is monitored.2, 3  In order to monitor the exchange 
activity, the ATP is captured on activated charcoal and the amount of 
radioactivity incorporated is determined by scintillation counting.  This assay has 
provided a highly sensitive assay for identifying the substrate specificity of a 
variety of synthetases and has been developed for high-throughput screening 
and kinetic measurements.4  However, it is limited by the relatively high amount 
of radioactive substrate used in each experiment, extensive liquid handling of 
radioactive materials and speed of analysis.  In order to circumvent the use of 
radioactive materials and to increase the speed of analysis, we developed a 
mass-based pyrophosphate exchange assay allowing for direct exchange 
analysis and reduction of background interference.  To validate this method, we 
tested a panel of previously characterized synthetases including TycA, an 
A-domain responsible for L-phenylalanine activation during tyrocidine 
biosynthesis; ValA, an orphan A-domain responsible for valine activation and 
tRNA synthetases for tryptophan (TrpRS) and lysine (LysRS).5-8 
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Results 
Hypothetically, mass spectrometry (MS) based pyrophosphate exchange 
can detect mass shifts on either side of the exchange equation.  We decided to 
introduce a heavy-atom label into the ATP starting material as γ-18O4-ATP based 
on its commercial availablility and literature precedent for its chemical synthesis.9 
An additional advantage of incorporating the label into ATP is that back 
exchange is favored by incubating the synthetase with an excess of unlabeled 
pyrophosphate, reducing the amount of label required for each reaction.  
Conditions for this assay were based on previously reported radioactive assay 
methods and simultaneously developed for both MALDI-TOF and ESI-LC mass 
spectrometry analyses.4, 10  Adenylation enzymes (200 nM) were incubated with 
1 mM γ-18O4-ATP, 1 mM amino acid, 5 mM MgCl2 and 5 mM pyrophosphate.  For 
MALDI-TOF MS analysis, reactions were quenched by mixing with an equal 
volume of 9-aminoacridine in acetone, identified as the optimal matrix for the 
detection of ATP in negative mode.11  For ESI-LC/MS analysis, reactions were 
quenched with an equal volume of acetone and separated from contaminating 
salts by using a Hypercarb graphitic matrix column (Thermo, Inc.), which 
dependably retains charged metabolites by charge quadrupole and hydrophobic 
interactions.12, 13  ATP was eluted from the column with an isocratic gradient of 
17.5% ACN in 20 mM ammonium acetate buffer (pH 6) and detected in negative 
ion mode.   
Observation of the 8 Da mass shift, caused by back exchange of 
unlabeled pyrophosphate leading to the formation of γ-16O4-ATP and 
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consumption by γ-18O4-ATP, allows for the quantification of enzyme activity. 
(Figure II-2) The enzyme activity was quantified as the integrated peak ratio of 
γ-16O4-ATP to all ATP species in the reaction mixture.  As the species being 
compared in the reaction mixture are isotopologues of ATP, peak integration and 
the subsequent signal ratio is quantitative in mass spectrometric analysis, as 
there should be no difference in ionization efficiency due to differences in 
chemical composition.  The observed mass ratios correlated to the fraction of 
ATP-pyrophosphate exchange activity.  Using this strategy, 6 μL reaction 
incubations can be analyzed via MALDI-TOF MS in as little as 30 seconds and, 
with higher sensitivity, ESI-LC/MS in 5 minutes. 
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Figure II-2. ATP-PPi exchange. A: The exchange reaction, performed in the absence of thiolation  activity, 
measures equilibrium exchange of γ-18O4-ATP with 16O4-pyrophosphate. B: Time dependent formation of γ-
16O4-ATP and disappearance of γ-18O4-ATP with TycA, measured by MALDI-TOFMS. Intermediary masses 
correspond to 18O3, 18O2, and 18O1 peaks.14  
 
In order to show the utility of the mass based pyrophosphate exchange 
assay, we determined the limit of detection (LOD) for both MALDI-TOF and 
ESI-LC mass spectrometry (MS) analysis. (Figure II-3)  Known amounts of 
labeled and unlabeled ATP were added to TycA reaction mixtures with no amino 
acid present.  For ESI-LC/MS, the LOD was determined to be 3.4 μM (0.34% 
exchange), and for MALDI-TOF MS, a higher LOD of 10 μM (1% exchange) was 
observed.  A possible source for the higher LOD in MALDI-TOF MS samples is 
the ion suppression effects in MALDI-TOF MS caused by a large amount of salt 
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within the MALDI samples, which is eliminated in the ESI-LC/MS sample 
preparation by the use of the Hypercarb column.  Background levels of γ-16O4-
ATP found within commercial γ-18O4-ATP were estimated to be 3.4 μM by 
ESI-LC/MS and fall below the LOD threshold for MALDI-TOF MS analysis.  Both 
detection methods showed comparable sensitivity to reported radioactive 
pyrophosphate exchange assays. Under optimized radioactive conditions, as 
little as 50 pmol exchange (0.01%) has been detected.15 With the rapid 
MALDI-TOF method, 1% (60 pmol) exchange was detected, while with full scan 
ESI-LC/MS detection 0.1% (6 pmol) exchange was observed and with selected 
reaction monitoring ESI-LC/MS detection, the sensitivity was enhance by 
monitoring as little as  0.01% (600 fmol) exchange. 
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Figure II-3. Limit of Exchange Detection for MALDI-TOFMS, ESI-LC/MS and ESI-LC/MS/MS detection 
methods.  Top: MALDI-TOFMS detection (in triplicate) of γ-16O4-ATP in 1 mM γ-18O4-ATP in reaction mixture 
demonstrated reliable detection above 1 % exchange. Middle: Similar measurement using ESI-LC/MS 
detection permitted detection levels above 0.1% exchange.  Bottom:  Similar measurement using ESI-
LC/MS/MS detection permitted detection levels above 0.01% exchange.14 
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As some NRPS A-domains are not particularly soluble or active when 
heterologously expressed, longer incubation times may be necessary to identify 
the correct amino acid substrate.  Of particular concern in these cases is the 
hydrolytic stability of γ-18O4-ATP under typical assay conditions.  To test this, 
γ-18O4-ATP was incubated under assay conditions with 1) no enzyme (TycA), 2) 
no amino acid and 3) incorrect amino acid for up to 15 hours.  No loss of label 
was observed at up to 15 hours in assay buffer in the absence of enzyme, 
consistent with literature reports showing the relative stability of 18O-substituted 
phosphates in buffered solutions.16 (Figure II-4)  However, in the presence of 
enzyme or incorrect amino acid, slow exchange of the 18O labeled was observed 
after 2-5 hours. Incubation of γ-18O4-ATP with enzyme for 5 hours resulted in a 
decrease in γ-18O4-ATP of 45 - 60 %, and an increase of partially labeled ATP, 
whereas only a 14 - 24% increase in the formation of γ-16O4-ATP, corresponding 
to the loss of the bridging β−γ 18O, was observed under the same conditions.  
This indicates that non β−γ−bridging 18O atoms exchanged more rapidly than 
bridging 18O atoms.  As pyrophosphate exchange is only indicated by the 
complete loss of the bridging β−γ 18O, the slow loss of non-bridging labels can be 
compensated for by calculating the exchange as the ratio of unlabeled ATP 
divided by the sum of all ATP species normalized to the theoretical equilibrium 
16O/18O molar ratio (83.33% apparent exchange = 100% exchange).  Therefore, 
% exchange = (100/0.833) * 16O/(18O + 16O). 
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Figure II-4. 18O ATP lability in 15 hour time course with No TycA (), no Substrate (), glutamate () and 
phenylalanine (). Over 15 hours γ-18O4-ATP is stable when no enzyme is present.  γ-18O4-ATP only 
becomes significantly depleted after two hours when γ-18O4-ATP is incubated with TycA without amino acid 
or with incorrect amino acid present.  However, γ-16O4-ATP created by loss of all four 18O labels is still only 
25% while exchange of 1, 2 or 3 18O labels accounts for the decrease of γ-18O4-ATP detected.  The loss of 
18O labels can be corrected for by calculating the ratio of the area of γ-16O4-ATP to the area of total ATP and 
subtracting the substrate free control.14 
 
TycA, from tyrocidine biosynthesis, was chosen as the model synthetase 
to validate the mass spectrometry based pyrophosphate exchange assay.  TycA 
specificity has been extensively studied by the traditional radioactive 
pyrophosphate exchange assay.2, 4  To demonstrate amino acid selectivity, we 
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tested the full panel of proteinogenic amino acids with the addition of 
D-phenylalanine, a previously identified substrate of TycA.  Both L- and 
D-phenylalanine were identified as substrates of TycA, showing 70 – 100% 
exchange using both MALDI-TOF and ESI-LC/MS analysis. (Figure II-5) While 
lower rates of exchange were effectively measured by ESI-LC/MS analysis, due 
to the LOD for MALDI-TOF analysis (1% exchange), no exchange was observed 
for all other amino acids tested.  However, the signal could be enhanced by 
increasing the enzyme concentration and/or incubation times. 
 
 
 
Figure II-525. Amino Acid Activation by TycA. Top: ESI-LC/MS () and MALDI-TOFMS () detection of 
TycA substrate activation by ATP-PPi exchange. Bottom: Enhanced sensitivity of MALDI-TOFMS detection 
of TycA substrate activation by γ−18O4-ATP-PPi exchange.  Activities were monitored via MALDI-TOFMS by 
incubating 1μM TycA for two hours in assay reaction mixture.14 
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To further validate the mass-based assay, an additional ‘orphan’ 
synthetase, ValA, a valine activating A-domain, identified and verified by Shen 
and coworkers, was tested.5  The MALDI-TOF assay demonstrated appreciable 
levels of exchange for valine in accordance with previous studies. (Table II-1) 
Again, for all other amino acids tested, levels of exchange fell below the LOD for 
MALDI-TOF MS analysis, but low levels of exchange were easily detectable 
using either ESI-LC/MS analysis or longer incubation times with higher enzyme 
concentrations for the MALDI-TOF method.  
 
Table II-1.  Activity of Amino Acid Activating Enzymes14 
 
 
In addition to the aforementioned NRPS adenylation domains, two 
previously characterized tRNA synthetases from E. coli, TrpRS and LysRS,   
were also assayed using mass-based pyrophosphate exchange.  As shown in 
Table II-1, TrpRS and LysRS activate their cognate amino acids under standard 
assay conditions. No activation was observed for non-substrates.  
To demonstrate the applicability of the mass-based exchange assay for 
kinetics measurements, the exchange velocities for TycA were plotted versus 
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L-phenylalanine concentration. (Figure III-6) The apparent Michaelis-Menten 
kinetic parameters were calculated for the purpose of comparison to previously 
reported TycA apparent parameters. ESI-LC/MS analysis yielded an apparent KM 
of 67 ± 2 μM and apparent kcat of 92 ± 2 min-1. These values are consistent with 
previously described measurements which report KM values between 40 μM to 
13 μM.4, 7 
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Figure II-6. TycA L-phenylalanine substrate 
dependence Substrate dependence of TycA with 
L-Phe.  Data were measured in triplicate using the 
ESI-LC/MS method. 
 
Discussion 
The conventional radioactive pyrophosphate exchange assay has been an 
indispensible tool in identifying substrate specificity of isolated synthetases.  The 
assay described herein improves on the existing assay as a complement to the 
ever expanding repertoire of technologies available to investigate the 
biosynthesis of peptide natural products.3, 17-21  Mass based pyrophosphate 
exchange directly measures the mass isotopologue ratio and permits quantitative 
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analysis using both MALDI and ESI ionization allowing substrate identification 
and easy determination of exchange kinetic parameters.   
Additionally, our method provides practical advantages compared to the 
conventional assay.  The use of stable isotopes circumvents the labor and 
regulatory expenses related to the safe handling of radioactive materials while 
eliminating the potential for false results due to radioactive artifacts.  The speed 
of the mass-based assay compares favorably to conventional exchange methods 
which employ solid phase capture, centrifugation or TLC steps followed by liquid 
scintillation counting, typically requiring continuous monitoring of β−emission for 
up to 48 hours for maximal sensitivity.  γ-18O4-ATP is indefinitely stable at -80 °C 
in buffered solutions, while the low reaction volume used in our method (6 μL) 
permits over 3000 exchange reactions to be performed using 10 mg of 
γ-18O4-ATP, limiting the cost of the assay to 33 cents using commercial 
γ-18O4-ATP.  Additionally, the assay was designed to allow easy scale up of the 
reaction mixture, if necessary.  Mass-based detection can be performed in as 
little as 30 seconds per sample in our MALDI-TOF MS implementation, which 
has not yet been optimized for speed. Furthermore, the MALDI-based assay 
described herein requires little sample clean-up and handling prior to analysis.  
 Recently, microbial genomics initiatives have identified staggering 
numbers of gene clusters containing cryptic putative NRPS. NRPS A-domain 
substrate selectivity can be estimated by primary sequence analysis using 
homology modeling approaches or neural network algorithms.22, 23  However, 
subsequent to these in silico analyses, it is often necessary to provide 
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biochemical evidence supporting A-domain selectivity. The γ−18O4-ATP-PPi 
exchange system provides a rapid, sensitive and reproducible means to measure 
adenylation domain specificity.  
 
Materials and Methods 
Chemicals and general methods 
All chemicals were purchased from Sigma-Aldrich unless otherwise noted.  
γ−18O4-ATP was purchased from Cambridge Isotope Labs (Cambridge, MA). 
Protein concentrations were measured with Pierce® BCA Protein Assay Kit 
(Thermo Scientific). 
Mass Spectrometry 
MALDI-TOF MS analyses were performed on a Voyager-DE™ STR 
(Applied Biosystems, Inc.) using a nitrogen laser (337 nm).  Prior to analysis, 1 
μL of analyte/matrix mixture was spotted on to a stainless steel MALDI target.  
External mass calibration was performed in the reflectron mode using a mixture 
of γ-18O4-ATP and γ−16O4-ATP. Mass spectra were acquired in negative ion mode 
over a range of 450 to 1200 m/z.  Mass spectra for ATP-PPi exchange analysis 
were obtained by averaging 100 consecutive laser shots. Data acquisition and 
quantitative spectral analysis was conducted using Applied Biosystems 
DataExplorer software, version 4.5. 
ESI-LC/MS analyses were performed on a ThermoFinnigan LTQ linear ion 
trap mass spectrometer (Thermo Fisher Scientific, Waltham, MA) equipped with 
an ESI interface in negative ion mode.  Nitrogen was used both for the auxiliary 
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and sheath gas.  The auxiliary and sheath gases were set to 20 psi and 36 psi, 
respectively. The following instrumental parameters were used: capillary 
temperature 300 C; source voltage 4.5 kV; source current 100 μA capillary 
voltage -49.0 V; tube lens -148.30 V; skimmer offset 0.00 V; activation time 
50 ms with an isolation width of 1 m/z.  The sensitivity of the mass spectrometer 
was tuned by infusion of γ-16O4-ATP at a flowrate of 0.01 mL/min.  Samples were 
introduced by a Waters Acquity UPLC system (Waters, Milford, MA) with an 
injection volume of 5 μL. γ-18O4-ATP was separated from contaminating salts on 
a 5 μm Hypercarb column (3 x 50mm, ThermoFisher Scientific) with an isocratic 
method of 82.5% 20 mM ammonium acetate pH 6 containing 0.1% diethylamine 
and 17.5% acetonitrile over 5 minutes with a flow rate of 0.2 mL/min. A divert 
valve was used for the first two minutes to avoid introducing salts into the source 
and the retention time of ATP species under these conditions was 3 minutes. For 
ESI-LC/MS/MS studies, the selection reaction monitoring mode was used with 
collision energy of 20eV.  The mass transitions of (514  408, 410, 412, 414, 
416), (512  408, 410, 412, 414), (510  408, 410, 414), (508  408. 410) and 
(506  408) corresponding to unlabeled, partially labeled and fully labeled ATP 
were monitored. Data acquisition and quantitative spectral analysis was 
conducted using the Thermo-Finnigan Xcaliber software, version 2.0 Sur 1.   
Data Analysis 
Monoisotopic peak area was determined using the respective software for 
each method.  For MALDI-TOFMS analysis, the ratio of the area of γ−16O4-ATP 
(m/z 506) to the area of total ATP including unlabeled, partially labeled, fully 
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labeled and monosodium-coordinated ions (m/z 506, 508, 510, 512, 514, 528, 
530, 532, 534, 536) was calculated using Microsoft excel and adjusted to reflect 
actual incorporation based on maximum theoretical incorporation to yield percent 
exchange.  For ESI-LC/MS analysis, the ratio of the area of γ−16O4-ATP to the 
area of total ATP including unlabeled, partially labeled, fully labeled, 
monosodium-coordinated and sodium acetate adduct ions was calculated using 
Microsoft excel and adjusted to reflect actual incorporation based on maximum 
theoretical incorporation to yield percent exchange.   For ESI-LC/MS/MS, the 
ratio of the area of γ−16O4-ATP, taken as the area of the product ion (m/z 408), to 
the area of total ATP including unlabeled, partially labeled, and fully labeled ions, 
taken as the sum of the area of their respective product ions ((514  408, 410, 
412, 414, 416), (512  408, 410, 412, 414), (510  408, 410, 414), (508  408. 
410) and (506  408)), was calculated using Microsoft excel and adjusted to 
reflect actual incorporation based on maximum theoretical incorporation to yield 
percent exchange. 
Cloning, Expression and Purification of A-domains 
TycA Expression and Purification 
Overproduction of the 110kD His-tagged TycA PheATE was performed in 
E. coli BL21(DE3) bearing the vector pSU18-tycAPheATE-His.  In a 2.8-L baffled 
flask, 500 mL LB medium containing 30 μg/mL chloramphenicol was inoculated 
(1:100) with an overnight culture made from a fresh colony of the above strain 
and grown at 37°C in a 2.8L baffled flask until OD600 ~ 0.6. IPTG was then added 
to give a final concentration of 0.5 mM and the culture was incubated for an 
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additional 20 h at 30 °C. The cells were pelleted (30 min, 3750 rpm, 4 °C) and 
resuspended in binding buffer (500 mM NaCl, 20 mM NaH2PO4, 20 mM 
imidazole, pH 7.4). For cell lysis, DNase I (NEB, 0.2 U/mL) was added, the cells 
were disrupted using a French pressure  cell and filtered through a 0.45 μm filter. 
The protein was purified on a HisTrap FF column (GE Healthcare) on an ÄKTA 
chromatography system (GE Healthcare) using binding buffer with linearly 
increasing imidazole concentration (20–500 mM). The pure protein was then 
desalted with a HiTrap Desalting column using 20 mM Tris, pH 7.5 and stored in 
aliquots at –80°C in storage buffer containing 5% glycerol and 1 mM DTT. 
ValA Expression and Purification 
  Production of the 56.6 kDa his-tagged Val-A was performed in E. coli 
BL21(DE3) bearing the vector pBS3. The conditions for expression and 
purification are similar to those described above except 50 μg/ml kanamycin was 
added to the medium instead of chloramphenicol. 
Kinetic Parameters for TycA 
For TycA kinetic measurements, the reactions were performed as 
described with the following modifications: % exchange was measured over a 
range of L-Phe concentrations (0.118 – 0.15 mM) and rates were measured as 
single time points at 3 minutes. In all cases the % exchange of reactions did not 
exceed 12%.  The ‘apparent’ substrate dependence parameters, KM and kcat, 
were calculated from initial velocity time curves with varied L-Phe concentrations 
using a non-linear least square fit to the Michaelis-Menten equation.   
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CHAPTER III 
 
BIOSYNTHETIC STUDIES OF K-26 
Introduction 
K-26, isolated from Astrosporangium hypotensionis (NRRL 12379), is a 
member of a unique class of naturally occurring phosphonate containing peptides 
which incorporate a phosphonic acid analogue of tyrosine (Figure III-1).1  K-26 
was originally discovered via bioassay guided fractionation testing for inhibitors of 
angiotensin converting enzyme (ACE).  K-26 possesses potent ACE inhibition 
with an IC50 of 14.4 nM, which is comparable to the antihypertensive drug 
Captopril.2  NMR, mass spectrometry and synthetic studies have demonstrated 
that K-26 is a tripeptide consisting of N-acetylated L-isoleucine, L-tyrosine and the 
non-proteinogenic amino acid (R)-1-amino-2-(hydroxyphenyl)ethylphosphonic 
acid (AHEP).1, 2  AHEP is shared among several other K-26 analogues isolated 
from Streptosporangium and Actinomadura species, all with some ACE inhibitory 
activity.3  Despite the potent hypotensive capability of K-26 and related 
analogues, little is known about the biosynthetic pathway of K-26 and its AHEP 
moiety. 
 81 
 
 
Figure 26.  K-26 and Related Analogues.  K-26 and its analogues share the non-proteinogenic amino 
acid AHEP, highlighted in red.  These tripeptides all show inhibitory activity with ACE. 
 
In all previously studied phosphonate containing natural products, the 
phosphonate moiety is derived from the catalytic activity of phosphoenolpyruvate 
(PEP) mutase.4-8  PEP mutase catalyzes the intramolecular rearrangement of 
phosphoenolpyruvate to phosphonopyruvate; the biosynthetic precursor of all 
previously studied phosphonate natural products (Figure III-2).  Structurally, 
AHEP is radically different from all other naturally occurring phosphonates.  
Additionally, it is not readily apparent how a precursor of AHEP could form the 
elimination intermediate necessary for carbon-phosphorus bond formation 
catalyzed by PEP mutase.  In order to investigate the biosynthesis of K-26, it was 
necessary to verify its production in our hands, determine the structure and 
identify the biosynthetic precursors in order to reveal the genes required for K-26 
biosynthesis. 
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Figure 27.  C-P Bond Forming Pathway.  All previously investigated carbon-phosphorus 
bond containing natural products are derived from phosphonoacetaldehyde.  
Phosphonoacetaldehyde is formed subsequent to the PEP catalyzed transformation of 
PEP to phosphonopyruvate. 
 
Results 
Incorporation of isotopically-labeled precursors 
 From the original structural analysis performed by Seto and coworkers in 
1986, K-26 was determined to consist of N-acetyl L-isoleucine, L-tyrosine and the 
non-proteinogenic amino acid AHEP.1  To validate these findings and to shed 
light on the biosynthetic pathway of K-26 and AHEP, isotopically labeled 
precursors were pulse-fed to growing cultures of A. hypotensionis.9  The purpose 
of these experiments was to reveal the timing of precursor incorporation.  Initial 
studies by Ntai et al revealed that tyrosine is a precursor of AHEP and AHEP is a 
discrete precursor of K-26.  Additional studies revealed that each amino acid is 
incorporated independently and N-acetylation occurs after at least the first 
peptide bond is formed (Figure III-3). 
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Figure 28.  Precursor Incorporation into K-26.  Incorporation of 
tyrosine into AHEP indicates that AHEP is derived from tyrosine.  AHEP 
is incorporated intact into K-26 as is most likely a discrete precursor.  N-
acetylation occurs after the first peptide bond is formed. 
  
Decarboxylation of tyrosine is formally required for AHEP formation, 
therefore, tyramine was proposed as a logical biosynthetic intermediate.  D4-
tyramine was produced from D4-tyrosine by enzymatic decarboxylation catalyzed 
by tyrosine decarboxylase from Streptococcus faecalis.  Four different pulse-
feeding experiments of 1 mM D4-tyramine failed to show any incorporation into 
AHEP and K-2610 (Figure III-4).   
 
 
Figure 29.  Tyramine Incorporation.  Although decarboxylation is formally required for AHEP biosynthesis, 
D4-tyramine was not incorporated into K-26. 
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One possible biosynthetic route for K-26 consistent with the precursor 
incorporation studies includes a series of ligases.  To investigate this possibility, 
[1-13C]-N-acetyl-L-isoleucine-[ring-D4]-L-tyrosine and [1-13C]-L-isoleucine-
[ring-D4]-L-tyrosine were synthesized using traditional peptide methods.11-16  
Briefly, the amine of [ring-D4]-L-tyrosine was reacted with Boc anhydride to give 
the protected amine.  Boc-[ring-D4]-L-tyrosine was further protected by addition of 
benzyl bromide.  Subsequent reaction with TFA yielded the free amine.  The 
amine group of [1-13C]-L-isoleucine was protected by Cbz and coupled with the 
Bn-protected [ring-D4]-L-tyrosine under standard conditions.  The protecting 
groups were then removed using catalytic hydrogenation resulting in the fully 
deprotected peptide, [1-13C]-L-isoleucine-[ring-D4]-L-tyrosine.  L-isoleucine was 
reacted with [1-13C]-acetyl chloride and coupled with the benzyl-protected 
[ring-D4]-L-tyrosine as above.  The benzyl groups were removed by catalytic 
hydrogenation to give [1-13C]-N-acetyl-L-isoleucine-[ring-D4]-L-tyrosine.  
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Scheme III-1.  Synthesis of Stable Labeled Dipeptides 
 
After synthetic preparation of the stable-labeled dipeptide precursors, 
separate production cultures of A. hypotensionis were supplemented with 1 mM 
of each dipeptide or with water vehicle for four days.  A. hypotensionis was 
cultured in K26 production media following the production methods established 
by Yamato et al.1 After six days of incubation, the production cultures were 
harvested by centrifugation, separating the culture broth supernantant and the 
cell paste.  The culture broth was extracted by Diaion HP-20 polystyrene resin at 
pH 3.  K-26 was eluted from the resin with a 50% methanol solution.  The 
methanolic solution was evaporated in vacuo and the residue redissolved in 
methanol and subjected to mass spectrometric analysis.  Cultures that were 
supplemented with only water were used for reference. 
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The specific incorporation of the labeled dipeptides into K-26 was 
determined using the Selected Reaction Monitoring (SRM) method described by 
Ntai et al9.  This tandem mass spectrometry method fragments the [M-H] 
precursor ions of K-26 by collision-induced dissociation.  By prudently selecting 
the precursor and product isotopomer masses in a given experiment, it is 
possible to quantitate the isotopic enrichment in both the charged product ion 
and the neutral loss fragments. K-26 (m/z 534) characteristically fragments to 
AHEP (m/z 216) and Tyr-AHEP (m/z 379) under tandem mass spectrometry 
conditions.  Figure III-5 shows a chromatographic example of these mass 
spectrometry experiments. Incorporation of the labeled dipeptide, intact, would 
shift the precursor mass of K-26 by 5 amu.  However, if the dipeptide undergoes 
proteolytic cleavage, the possibility exists for the precursor mass of K-26 to shift 
by 4 amu or 1 amu depending on the incorporation of [ring-D4]-L-tyrosine or 
[1-13C]-L-isoleucine/[1-13C]-N-acetyl-L-isoleucine, respectively.   
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Figure 30.  SRM Detection of Precursor Incorporation. To detect incorporation of a proposed 
biosynthetic precursor into K-26, an SRM method was used.  Judicious selection of the precursor and 
product ion masses allows for calculation of label incorporation.  This example is from a control sample from 
a culture of A. hypotensionis without administration of a labeled precursor. Top: K-26 (m/z 534) 
fragmentation to AHEP (m/z 216).  Middle: K-26 + 5 (m/z 539) fragmentation to AHEP (m/z 216).  Bottom: K-
26 + 5 (m/z 539) fragmentation to AHEP + 4 (m/z 220). 
 
To monitor incorporation of the labeled dipeptides, we selected a specific 
precursor mass for K-26 (m/z 534, 539) and monitored the characteristic product 
ions m/z 216 and m/z 220, which correspond to AHEP and AHEP+5.  If the 
dipeptides are incorporated intact, we would expect to observe fragmentation of 
the K-26+5 peak (m/z 539) to AHEP (m/z 216).  Fragmentation of the K-26+5 
(m/z 539) peak to AHEP+4 (m/z 220) would indicate that the dipeptide was 
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hydrolyzed and D4-tyrosine was incorporated into AHEP.  Additional experiments 
monitored the possible incorporation of inidividual labeled amino acids, if 
hydrolysis occurred. Least squares fitting of labeled isotopomer data permitted 
the extraction of the relative isotopic enrichments of each amino acid in K-26.  
Based on the isotopic incorporation data, the dipeptides were not incorporated 
intact. (Figure III-6) 
 
H
N
O
O
N
H O
H
N PO3H
OH
OH
H
N
O
O
N
H O
OH
OH
D
D
D
D
H2N
O
N
H O
OH
OH
D
D
D
D
(+1) 0%
(+4) 3%
(+5) 0%
(+1) 4%
(+4) 2%
(+5) 0%
 
Figure 31.  Dipeptide Incorporation Studies.  Precursor Incorporation studies with stable-labeled 
didpeptide substrate indicate that the dipeptides were not incorporated intact. 
 
The labeled tyrosine and AHEP incorporation studies revealed that 
tyrosine is a precursor to AHEP and AHEP is a discrete precursor to K-26.  
However, tyramine is not incorporated indicating that decarboxylation and 
phosphonylation of tyrosine may occur in concert or that the tyramine 
intermediate is not released before phosphonylation. Moreover, the labeled 
isoleucine and dipeptide experiments indicate that each amino acid is 
incorporated individually and that N-acetylation occurs after peptide bond 
formation.   
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Biosynthetic hypothesis 
Based on the stable-labeled precursor incorporation studies, we 
hypothesized that K-26 is biosynthesized via the NRPS paradigm.17 As described 
in Chapter I, NRPS are modular multidomain proteins capable of synthesizing 
small peptides containing non-proteinogenic amino acids.  As feeding studies 
indicate that AHEP is a discrete precursor of K-26, we hypothesize that AHEP is 
biosynthesized prior to peptide bond formation.  In this case, shown in Figure 
III-7, L-isoleucine, L-tyrosine and AHEP would be activated by individual 
A-domains, loaded onto the corresponding T-domains and peptide bond 
formation would be catalyzed by the C-domain resulting in the formation of 
des-acetyl-K-26 (dK-26).  Then either on the final T-domain or after release of the 
peptide by the Te-domain, N-acetylation would occur resulting in formation of 
K-26.  Our proposed gene cluster would consist of an N-acetyltransferase, NRPS 
with a domain string of A-T-C-A-T-C-A-T-Te and hypothetical proteins of 
unknown function responsible for AHEP biosynthesis.   
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Figure 32 Possible biosynthetic route for K-26 formation.  
Isoleucine, tyrosine and AHEP would be loaded onto T-domains of an 
NRPS.  Following peptide bond formation, dK-26 would be N-acetylated 
to give K-26 
 
Genetic Analysis 
With the results of the precursor incorporation studies and a biosynthetic 
hypothesis in hand, we turned to genetic analysis to identify the prospective gene 
cluster of K-26.  In order to rapidly identify the gene cluster for K-26, the genome 
of A. hypotensionis was sequenced and annotated by The Institute of Genomic 
Research (TIGR) providing approximately 10 times coverage.  From this data, we 
identified 11 NRPS gene clusters, four of which may potentially be involved in 
tripeptide biosynthesis: pps8, pps6, pps3 and pps1.  Additionally, no PEP mutase 
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was found within the A. hypotensionis genome, supporting our hypothesis that 
AHEP is formed via a novel biosynthetic route for phosphonate formation. 
In the hope that substrate specificity of the A-domains of prospective K-26 
gene clusters would provide evidence to determine which tripeptide biosynthetic 
cassette is responsible for K-26 biosynthesis, we extracted the 8- to 10- amino 
acid specificity code involved in discrimination of amino acid binding within the A-
domain binding pocket, as described by Challis et al  and Stachelhaus et al.18, 19  
The prospective gene clusters and their A-domain specificity codes are shown in 
Table III-1.  Out of these four gene clusters, pps3 seems like the most promising 
gene cluster, however, no N-acetyltransferase nor proteins of unknown function 
are clustered with this NRPS.  As no clear gene cluster for K-26 biosynthesis was 
revealed by genomic evaluation, we turned to traditional biochemical methods to 
isolate of the protein machinery responsible for K-26 biosynthesis from cell-free 
extract of A. hypotensionis. 
 
Table III-1.  Prospective K-26 NRPS Gene Clusters 
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Reverse Genetic Analysis 
 As genomic analysis did not provide us with sufficient evidence to identify 
the biosynthetic gene cluster of K-26, we were forced to attempt to identify the 
gene cluster using traditional biochemical methods.  Based on the structure of K-
26, there are three possible handles for biochemical assay development: N-
acetylation, peptide bond formation and AHEP biosynthesis.  To begin 
biochemical investigations, N-acetylation of dK-26 was first investigated, as most 
acetyltransferases only require acetyl-Coenzyme A (Ac-CoA) and substrate for 
activity.   Second, the mass-based pyrophosphate exchange assay was used to 
test for L-isoleucine, L-tyrosine and AHEP activation required for peptide bond 
formation in nonribosomal peptide biosynthesis. 
N-acetyltransferase Isolation 
  Based on the precursor incorporation experiments, N-acetylation occurs 
after peptide bond formation in K-26 biosynthesis.  To identify the 
N-acetyltransferase (NAT) involved in K-26 biosynthesis, Ioanna Ntai developed 
a mass spectrometry based assay.20  Protein fractions generated from A. 
hypotensionis cells shown to produce K-26 were incubated with dK-26 and 
acetyl-CoA.  After incubation, the reaction mixture was subjected to mass 
spectrometry utilizing selected reaction monitoring (SRM) specifically monitoring 
the fragmentation of the precursor, dK-26 ([M-H] 492); the product, K-26 ([M-H] 
534) and the internal standard D3-K26 ([M-H] 537) to AHEP ([M-H] 216).  From 
proteomic analyses of SDS-PAGE gel slices of partially purified protein mixtures, 
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three NATs were identified: ORF1625, ORF5817 and ORF6213.  After 
heterologous expression and purification, the purified proteins were tested for 
N-acetylation of dK-26, Ile-Tyr-(S)-AHEP, Ile-Tyr and Ile-Tyr-Tyr.  The activities 
of these NATs are summarized in Table III-2.   
 
Table III-2.  Summary of NAT Activity 
 
 
Of these NATs, ORF6213 showed the most N-acetyltransferase activity on 
dK-26.  ORF6213 is within the pps1 tripeptide gene cluster.  However, the first 
two A-domains of the NRPS of pps1 have the same 8- to 10- amino acid 
specificity code within the A-domain amino acid binding pocket indicating that 
both A-domains are likely responsible for activating the same amino acid.  To 
determine whether ORF6213 is the NAT responsible for acetylation of dK-26, 
possibly as the result of off-target activity, an attempt was made to measure the 
KM.  Protein fractions (30 μL) were incubated with Ac-CoA and dK-26 (0.5 mM – 
5 mM) at 30 oC for 4 hours. The reaction was quenched by addition of an equal 
volume of methanol and subjected to mass spectrometry analysis.   
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The KM of ORF6213 was determined to be higher than 5mM dK-26 (Figure 
III-8).  Higher concentrations of dK-26 could not be tested due to the limited 
solubility of dK-26.  These results indicate that the acetylation of dK26 may be 
due to promiscuous NATs and not a dedicated NAT clustered with the peptide 
bond forming machinery.  Since these experiments did not unambiguously 
identify the gene cluster of K-26, we proceeded to use our second handle, 
peptide bond formation, in an attempt to isolate the proteins responsible for K-26 
biosynthesis. 
 
 
Figure 33. Kinetic Characterization of ORF6213. The KM of 
Orf6213 is greater than 5mM.  Higher dK-26 concentrations 
could not be tested due to the low solubility of dK-26. 
 
 
Adenylation Enzyme Isolation 
 Based on our hypothesis, K-26 is biosynthesized via the NRPS paradigm 
where A-domains are involved in amino acid selectivity and promote the reaction 
of the cognate amino acid with ATP to create the aminoacyl adenylate and 
release of inorganic pyrophosphate.17  This reaction is reversible, in most cases, 
and can be followed by the pyrophosphate exchange assay.  To purify the 
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proteins responsible for amino acid activation in K-26 biosynthesis, protein 
fractions were tested for exchange activity with Ile, Tyr and AHEP, with a 
negative control performed concurrently.21-25 To test for this activity, we used the 
mass-based pyrophosphate exchange assay as described in Chapter II.  Briefly, 
partially purified protein fractions were incubated with 1 mM γ-18O4-ATP, 5 mM 
pyrophosphate and 1 mM amino acid substrate in the presence of magnesium.  
After incubation, the reaction was quenched and the mixture was subjected to 
mass spectrometry analysis.  Activity was measured as the percentage of 
unlabeled ATP, from the back exchange of pyrophosphate, to total ATP, adjusted 
to reflect the probability of incorporation.  
 With a sensitive and accurate assay in hand, we began our initial 
purification of adenylation enzymes from A. hypotensionis cell-free extract with 
the goal of proteomic identification of the enzymes responsible for activity and 
subsequent correlation of the proteins to the biosynthetic gene cluster of K-26.  
Figure III-9 is a comprehensive chart of all the purification methods used.  The 
following represents the final attempt at purification: 
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Figure 34. Overview of adenylation enzyme purification methods.  The methods used for final 
purification are highlighted in light red.  
 
A. hypotensionis was cultured in K26 production media following the 
production methods established by Yamato et al. The production cultures were 
harvested by centrifugation, separating the culture broth and the cell paste. The 
broth was adjusted to pH 3 and extracted with Diaion HP-20 resin.  K-26 was 
eluted from the HP-20 resin with a 50% methanol solution.  The methanolic 
solution was evaporated in vacuo and the residue redissolved in methanol and 
subjected to mass spectrometric analysis, confirming the production of K-26.  
The cell paste, of A. hypotensionis cultures verified to produce K-26, was washed 
with 20% glycerol. The mycelia were frozen in liquid nitrogen for storage at 
-80oC.  Protein purification was initiated by suspending approximately 60 g of 
frozen mycelia in general enzyme buffer (GEB) and rupturing the cells using a 
French pressure  cell.  Nucleic acids were precipitated by streptomycin sulfate 
addition followed by centrifugation.  After removal of the precipitated nucleic 
acids, crude protein fractionation was performed on the supernatant by 
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ammonium sulfate precipitation at 30%, 55% and 75% saturation.  After 
centrifugation, each ammonium sulfate pellet was dialyzed overnight against 
GEB to remove excess salt and the dialysate was tested for activity with L-
isoleucine, L-tyrosine and AHEP.  Initial testing of the dialysate revealed that 
most of the activity precipitated in the 55% ammonium sulfate fraction. (Figure III-
10)  
 
 
Figure III-10.  Ammonium Sulfate Fractionation.  Pyrophosphate exchange analysis of ammonium sulfate 
fractions of the A. hypotensionis proteome revealed that the 55% saturation fraction contained most of the 
proteins responsible for activating the amino acid precursors. Tyr = red, Ile = green, AHEP = purple and no 
amino acid control = light blue 
 
After ammonium sulfate precipitation, further fractionation of the 55% 
saturation fraction was performed by anion exchange chromatography using 
Q-sepharose resin. (Figure III-11) Pyrophosphate activity for tyrosine and 
isoleucine co-eluted, while no activity was detected for AHEP or the negative 
control. 
 
0
20
40
60
80
100
75% AS 55% AS 30% AS 
Pe
rc
en
t E
xc
ha
ng
e
 98 
 
 
Figure 35.  Q-sepharose Fractionation.  After ammonium sulfate precipitation, the 55% saturation fraction 
was further fractionated by Q-sepharose anion exchange.  Pyrophosphate activity for tyrosine and isoleucine 
co-eluted, while no activity was detected for AHEP or the negative control. Tyr = red, Ile= green, AHEP = 
purple, no amino acid control = light blue, absorbance at 280 = dark blue. 
 
The active fractions from the Q-sepharose column were combined, 
concentrated and applied to a DEAE sepharose anion exchange column, in an 
attempt to further purify the proteins responsible for the observed pyrophosphate 
exchange activity.  (Figure III-12) 
 
 
Figure 36. DEAE-sepharose Fractionation. After separation by Q-sepharose resin, the active fractions 
were further fractionated by DEAE anion exchange.  Pyrophosphate activity for tyrosine and isoleucine co-
eluted, while no activity was detected for AHEP or the negative control. Tyr = red, Ile= green, AHEP = 
purple, no amino acid control = light blue, absorbance at 280 = dark blue 
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The active fractions were combined, concentrated and divided in half to 
continue purification using two methods: hydrophobic interaction, using Butyl 
Fast Flow resin, and size exclusion, using Sephacryl S-200 resin. (Figure III-13)  
 
 
 
Figure 37.  Hydrophobicity and Size Exclusion Fractionation.  After DEAE anion exchange fractionation, 
half of the pooled fractions were applied to either a Butyl Fast Flow column ( hydrophobic separation, top 
graph) or a Sephacryl S-200 column (size exclusion, bottom graph).  Some separation of the pyrophosphate 
exchange activity for tyrosine and isoleucine was observed. Tyr = red, Ile= green, AHEP = purple, no amino 
acid control = light blue, absorbance at 280 = dark blue 
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The active fractions were subjected to SDS-PAGE analysis and two 
fractions were sent for proteomics analysis (Figure III-14): Sephacryl S-200 
fraction 11, which showed 42% activity for L-isoleucine and 0% activity for 
L-tyrosine, and Butyl Fast Flow fraction B9, which showed 30% activity for 
L-isoleucine and 21% activity for L-tyrosine. 
 
 
Figure 38.  SDS-PAGE of active fractions for isoleucine and/or 
tyrosine adenylation.  Lane 1: Marker, Lane 2: Sephacryl S-200 
fraction 11, Lane 3: Sephacryl S-200 fraction 14, Lane 4: ButylFF 
fraction B8, Lane 5: Butyl FF fraction B9, Lane 6: ButylFF fraction B11, 
Lane 7: Marker.  Sephacryl S-200 fraction 11 and ButylFF fraction B9 
were subjected to proteomics analysis. 
 
Proteomics analysis of these two samples revealed 101 proteins, two of 
which may correspond to adenylation activity: isoleucyl tRNA synthetase and a 
hypothetical protein containing an AMP-binding domain.  To verify the proteomics 
results and to test whether the tyrosine adenylation activity was also due to a 
tyrosyl tRNA synthetase, a radioactive tRNA loading assay was performed using 
active fractions from a duplicate purification where instead of using 
hydrophobicity or size exclusion, the protein mixture was subjected to anion 
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exchange fractionation using MonoQ resin.26  It should be noted that pooled 
active fractions were tested for pyrophosphate exchange against a panel of 
amino acids to ensure our isolation of isoleucine and tyrosine activating 
enzymes. (Figure III-15) 
 
 
Figure 39.  Pyrophosphate Exchange Analysis of Fractions.  To verify the isolation of isoleucine and 
tyrosine activating enzymes, at each step, pooled fractions were tested for pyrophosphate activity against a 
panel of amino acids.   
 
The MonoQ fraction active for both L-isoleucine and L-tyrosine catalyzed 
the loading of tritiated L-isoleucine and L-tyrosine onto E. coli tRNA, in separate 
experiments, confirming the isolation of tRNA synthetases from A. hypotensionis. 
(Figure III-16)  
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Figure 40. tRNA Charging Assay.  To test for the presence of tRNA synthetases, the traditional radioactive 
tRNA charging assay can be performed.  For example, radiolabeled L-tyrosine and tyrosine specific tRNA 
would be incubated with a protein mixture to test for the presence of TyrRS in a protein mixure.  If TyrRS is 
present, the Tyr tRNA would be loaded with the labeled L-tyrosine.  
 
Additionally from genomic analysis, the hypothetical protein identified via 
proteomics was part of a small gene cluster containing an N-acetyltransferase.  
To investigate whether this cluster was responsible for K-26 biosynthesis, we 
heterologously expressed and purified the N-acetyltransferase (NAT 97747) and 
tested for N-acetylation of dK-26. (Figure III-17) Neither dK-26 nor Ile-Tyr were 
acetylated. 
 
 
Figure 41.  SDS-PAGE of NAT 97747.  Lane 1: Marker; Lane 2: 
Uninduced; Lane 3: Induced; Lane 4 Flow-through; Lane 5: His-
Trap Purified; Lane 6: Desalted; Lane 7: Marker. 
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Discussion 
 Identification of the biosynthetic genes of K-26 presents a unique 
challenge.  In our hands, K-26 is produced by A. hypotensionis at approximately 
10 μg/L.9  At such low levels of production, the only method for verifying K-26 
production is through mass spectrometry.  The tripeptide nature of K-26 and the 
unique pharmacophore of AHEP limit the handles available to exploit for 
biosynthetic investigations.  The required genes for K-26 biosynthesis are limited 
to an N-acetyltransferase, peptide bond forming machinery and those required 
for AHEP biosynthesis.  Traditional precursor incorporation experiments with 
stable-labeled biosynthetic precursors allowed us to propose a NRPS 
biosynthetic mechanism for K-26 formation and a possible pathway for AHEP 
formation from tyrosine.9, 10 Although the genome of A. hypotensionis has been 
sequenced, the biosynthetic cassette for K-26 remains cryptic.  
As an N-acetyltransferase is formally required for K-26 formation, it was 
selected as the initial handle to examine K-26 biosynthesis.20  The results of the 
precursor incorporation studies suggest that N-acetylation occurs after formation 
of the peptide bond between L-isoleucine and L-tyrosine.  Activity guided protein 
purification and subsequent proteomics analysis identified three 
N-acetyltranferases, which were heterologously expressed in E. coli: ORF 1625, 
which was isolated multiple times; ORF5817, which had high sequence coverage 
in proteomics analysis and ORF6213, which is situated neighboring pps1, an 
NRPS tripeptide gene cluster.  While heterologously expressed ORF1625 and 
ORF5817 showed limited turnover of dK-26, ORF6213 showed moderate 
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turnover for dK-26 and L-Ile- L-Tyr and good turnover for L-Ile-L-Tyr-L-Tyr.  The KM 
of ORF6213 indicates that ORF6213 may not be dedicated to K-26 biosynthesis; 
however, it may be the N-acetyltransferase responsible for acetylation of dK-26 
through off-target activity.   Further analysis of the 8- to 10- amino acid specificity 
code within the A-domains of pps1 revealed that the first and second A-domains 
within the cluster have identical specificity codes and predict glycine 
incorporation while the third A-domain shows homology to aspartate activating 
A-domains making pps1 an unlikely candidate gene cluster for K-26 biosynthesis.  
As investigation of N-acetyltransferase activity did not reveal the 
biosynthetic genes of K-26, peptide formation was selected as the second handle 
to analyze.  Typically, small peptides containing non-proteinogenic amino acids 
are biosynthesized by the NRPS paradigm.  To investigate peptide bond 
formation, we chose to use the mass-based pyrophosphate exchange assay as 
NRPS A-domains, tRNA synthetases and AMP-binding peptide ligases usually 
catalyze the formation of an aminoacyl adenylate.  Pyrophosphate exchange 
experiments were carried out with L-isoleucine, L-tyrosine and AHEP.  
L-isoleucine and L-tyrosine showed pyrophosphate exchange activity, while 
AHEP did not.  The lack of exchange activity was not wholly unexpected as there 
are some A-domains and tRNA synthetases that do not undergo reversible 
exchange.  By following the L-isoleucine and L-tyrosine pyrophosphate exchange 
activity, an isoleucyl tRNA synthetase and one hypothetical protein with an 
AMP-binding domain were identified by proteomics analysis.  However, no NRPS 
or L-tyrosine activating enzymes were identified.   To confirm the isolation of 
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isoleucyl tRNA synthetase and to explore the possibile isolation of tyrosyl tRNA 
synthetase, we performed the traditional tRNA charging assays for both 
L-isoleucine and L-tyrosine.  Both E. coli isoleucyl and tyrosyl tRNAs were 
charged with the corresponding amino acid indicating the pyrophosphate 
exchange activity observed with both L-isoleucine and L-tyrosine was caused by 
tRNA synthetases.  To determine whether the protein of unknown function with 
an AMP-binding motif was involved in K-26 biosynthesis, NAT 97747 within the 
same gene cluster was heterologously expressed and purified.  The purified 
protein showed no acetylation of dK-26 or L-Ile- L-Tyr.   
Unfortunately, we have not been able to unambiguously identify the gene 
cluster responsible for K-26 biosynthesis.  The ability to identify the proteins 
responsible for K-26 biosynthesis is limited by the production levels of K-26.  
Correspondingly, the proteins involved in K-26 are presumably also produced at 
extremely low levels.  In order to isolate the proteins responsible for K-26 
biosynthesis, it will be necessary to increase the production level of K-26 in A. 
hypotensionis or identify another producer with higher production levels.   
We have identified another producer of K-26, and two additional 
analogues, Sphaerosporangium rubeum. However, the production levels of S. 
rubeum are similar to those of A. hypotensionis.  Briefly, seed culture of S. 
rubeum was grown in K26S media.  After seed culture, S. rubeum was grown in 
6 different media for K-26 analogue production.  These cultures were extracted 
using the methods previously described.  AHEP containing peptide natural 
products characteristically fragment to AHEP when subjected to tandem mass 
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spectrometry analysis.  Using precursor ion scanning, we identified K-26, 
SF5213B and SF5213C in S. rubeum culture broth.  (Figure III-18) 
 
 
Figure 42.  K-26 and Analogue Production by S. rubeum.  Precursor ion scanning mass spectrometry 
experiments of S. rubeum production cultures identified production of K-26, SF-2513B and SF-22513C. 
 
The results of the aforementioned experiments seem to indicate that the 
N-acetyltransferase responsible for acetylating dK-26 may not be clustered with 
the rest of the genes responsible for K-26 biosynthesis.  Speculatively, if 
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acetylation is occurring through off-target activity of a variety of 
N-acetyltransferases and peptide bond formation is through a promiscuous 
ligase, the only genes required for K-26 biosynthesis are those encoding the 
proteins responsible for AHEP formation.  This lack of clustering may limit the 
handles available for investigation to AHEP formation.  Additional difficulties lie in 
the lack of information about the precursors of AHEP.  From the stable-labeled 
precursor incorporation experiments, we know that AHEP is derived from 
L-tyrosine and AHEP is a discrete precursor of K-26, however, during the above 
experiments, at no time was dK-26 or K-26 formation observed when 
L-isoleucine, L-tyrosine and AHEP were incubated with cell-free extract of A. 
hypotensionis.  In order to identify the proteins required for AHEP formation, the 
phosphate source and additional cofactors will have to be identified.  Additionally, 
as AHEP formation is expected to be the rate limiting step in K-26 biosynthesis, it 
will be necessary to develop an extremely sensitive assay for AHEP formation. 
Complementary to reverse genetic experiments, heterologous expression 
of A-domains within prospective K-26 gene clusters has been undertaken.  While 
this has been an ongoing route to identify of the K-26 biosynthetic cassette, 
expression of K-26 A-domains in heterologous hosts has proved to be 
challenging, limiting the success of this endeavor.  Recent reports have indicated 
that small MbtH-like proteins often found near or within NRPS gene clusters may 
play a role in increasing the solubility and expression levels of A-domains when 
co-expressed in heterologous hosts.  Future work co-expressing these proteins 
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may help to identify and/or eliminate prospective gene clusters involved in K-26 
biosynthesis. 
 
Materials and Methods 
Chemicals and general methods 
All non-aqueous reactions were performed under ultra high purity argon in 
flame-dried glassware.  All chemicals were purchased from Sigma-Aldrich at the 
highest purity available unless otherwise noted.  γ-18O4-ATP, [ring-D4]-L-tyrosine, 
[1-13C]-acyl chloride and [1-13C]-L-isoleucine were purchased from Cambridge 
Isotope Labs (Cambridge, MA).  Reactions were monitored by thin-layer 
chromatography (TLC) using E. Merck precoated silica gel 60 F254 plates.  
Visualization was accomplished by UV light and aqueous stain followed by 
charring on a hot plate.  Flash chromatography was performed using the 
indicated solvents and silica gel (230-400 mesh).  1H and 13C NMR were 
recorded on Bruker 300, 400 or 500 MHz spectrometers.   
 
Synthesis of [ring-D4]-tyramine   
[ring-D4]-L-tyrosine (100 mg, 0.54 mmol) was dissolved in H2O (100 mL) by 
microwave heating.  A suspension of tyrosine decarboxylase from Streptococcus 
faecalis (2.0 mg, 0.05 unit/mg) and pyridoxal-5-phosphate (7 mg, 0.026 mmol) in 
acetate buffer (4 mL of 0.1 M, pH 5.5) was added to the cooled tyrosine solution.  
The solution was incubated at 37oC for 3 hr.  The reaction was stopped by 
heating to boiling.  Tyramine was purified using Millipore Ultra 5000 MWCO 
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centrifugal filter devices (3450g, 30 min).  The filtrate was concentrated in vacuo 
and passed through a Dowex 1-x8 anion exchange column.  Evaporation of the 
eluent gave [ring-D4]-tyamine as a tan powder (98% D, 97% yield). 1H NMR (300 
MHz, D2O): δ2.747 (t, J = 7.2Hz, 2H), 3.058 (t, J = 7.2Hz, 2H).  13C NMR (100 
MHz, D2O): δ155.33, 129.80 (t, J= 19Hz), 127.68, 115.66 (t, J= 19Hz), 40.79, 
31.89  
 
Synthesis of [1-13C]-N-Ac-L-Ile-[ring-D4]-L-Tyr 
N-Boc-[ring-D4]-L-Tyr. A solution of 100 mg [ring-D4]-L-tyrosine (1 eq, 100 mg, 
0.54 mmol) in dioxane (7.5 mL), H2O (7.5 mL) and NaOH (1M, 1 eq, 540 μL, 0.54 
mmol)  was stirred and cooled in an ice-water bath.  Di-tert-butyl dicarbonate (1.1 
eq, 136 μL, 0.59 mmol) was added and the solution was stirred overnight.  The 
solution was concentrated in vacuo and the aqueous solution was acidified to pH 
2.  The acidified aqueous solution was extracted with EtOAc (3 x 20 mL).  The 
organic layers were pooled, washed with brine (3 x 100 mL), dried (MgSO4) and 
evaporated to give a white crystalline powder. (0.48 mmol, 138.9 mg, 89.5%) 1H 
NMR (400 MHz, DMSO): δ9.15 (s, 1H), 3.95 (m, 1H), 2.85 (m, 1H), 2.69 (s, 1H), 
1.36 (s, 9H).  13C NMR (100 MHz, DMSO): δ174.13, 155.83, 128.18, 78.38, 
55.90, 35.95, 28.55.   
N-Boc-[ring-D4]-L-Tyr(OBn)-COOBn.  A solution of N-Boc-[ring-D4]-L-Tyrosine 
(1 eq, 100 mg, 0.35 mmol), in dry DMF (3 mL) at room temperature was treated 
with potassium carbonate (2.5 eq, 26.7 mg, 0.70 mmol), benzyl bromide (2.5 eq, 
83 μL, 0.70 mmol), and tetrabutylammonium iodide (0.125 eq, 16 mg, 0.044 
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mmol).  The reaction mixture was stirred at room temperature overnight.  The 
aqueous mixture was extracted with ether (3 x 10 mL).  The organic layers were 
combined washed with 1 N HCl (3 x 30 mL) and brine (3 x 30 mL), dried (MgSO4) 
and concentrated in vacuo leaving a yellow solid. (0.24 mmol, 110.8 mg, 68.6%) 
1H NMR (500 MHz, DMSO): δ9.19 (s, 1H), 7.43-7.26 (m, 10H), 5.07 (s, 2H), 4.12 
(s, 1H), 3.33 (s, 2H), 2.85 (m, 1H), 2.69 (m, 1H), 1.32 (s, 9H). 13C NMR (125 
MHz, DMSO): δ172.53, 156.27, 155.80, 137.57, 136.28, 128.79, 128.71, 128.48, 
128.34, 128.11, 128.00, 127.61, 117.31, 78.65, 69.52, 66.17, 56.20, 35.93, 
28.51. 
[ring-D4]-L-Tyr(OBn)-COOBn.  Boc-[ring-D4]-L-Tyr(OBn)-COOBn (1 eq, 50 mg, 
0.11 mmol) was treated with TFA (236eq, 2 mL, 26 mmol) in the presence of 
anisole (16 eq, 0.2 mL, 1.8 mmol) in an ice-bath for 30 min.  TFA was then 
removed by evaporation to give white crystals. (.095 mmol, 34.5 mg, 85.9%) 1H 
NMR (500 MHz, DMSO): δ8.446 (s, 2H), 7.441-7.255 (m, 10H), 5.061 (s, 2H), 
4.318 (t, J = 6.5Hz, 1H), 3.110-3.001 (m, 4H). 13C NMR (125 MHz, DMSO): 
δ171.32, 157.51, 137.23, 136.14, 131.64, 128.77, 128.56, 128.42, 128.23, 
128.09, 127.89, 127.53, 116.27, 77.83, 69.73, 53.78, 38.44.  
[1-13C]-N-Ac-L-Isoleucine.  To a solution of L-Isoleucine (1 eq, 300 mg, 2.3 
mmol) in NaOH (4M, 3 eq, 1.75 mL, 7 mmol) at 0oC, [1-13C]-acyl chloride (1.1 eq, 
178 μL, 2.5 mmol) was added in 5 portions over 50 min.  The mixture was 
acidified to pH 1.5 with HCl and extracted with EtOAc (3 x 10 mL).  The organic 
layers were combined, dried (MgSO4) and concentrated in vacuo to give a white 
powder. (0.58 mmol, 100 mg, 25%) 1H NMR (500 MHz, DMSO): δ7.98 (t, J = 
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5Hz, 1H), 4.17-4.13 (m, 1H), 1.85 (s, 3H), 1.75 (m, 1H), 1.37 (m, 1H), 1.16 (m, 
1H), 0.90-0.81 (m, 5H). 13C NMR (125 MHz, DMSO): δ173.55, 169.76, 56.60, 
36.67, 25.10, 22.89, 15.96, 11.67.  
 [1-13C]-N-Ac-L-Ile-[ring-D4]-L-Tyr(OBn)-COOBn.  [1-13C]-N-Ac-L-Isoleucine 
(1.05 eq, 18.0 mg, 0.104 mmol), [ring-D4]-L-Tyr(OBn)-COOBn (1 eq, 36.1 mg, 
0.099 mmol) and HOBt (1.1 eq, 14.7 mg, 0.109 mmol) were dissolved in DMF 
(10 mL).  The solution was cooled in an ice-bath and treated with EDC (1.1 eq, 
20.9 mg, 0.109 mmol) and 2,4,6-Trimethylpyridine (1 eq, 13 μL, 0.099 mmol).  
The mixture was stirred at 0 oC for 1 hr, allowed to warm to room temperature 
and stirred overnight.  The reaction was diluted with EtOAc, washed with 1N HCl 
(3 x 30 mL), 1N NaHCO3 (3 x 30 mL) and brine (3 x 30 mL), dried (MgSO4) and 
concentrated in vacuo to give white crystals. (46.3 mg, 0.089 mmol, 89.6%)  1H 
NMR (500 MHz, DMSO): δ8.42 (d, J = 7Hz, 1H), 7.80 (dd, J = 8.75Hz, 1H), 7.43-
7.22 (m, 10H), 5.04-4.88 (m, 4H), 4.44 (q, J = 7.5Hz, 1H), 4.21 (t, J = 6Hz, 1H), 
2.96-2.86 (m, 2H), 1.62 (m, 1H), 1.34 (m, 1H), 0.99 (m, 1H), 0.78-0.71 (m, 5H) 
13C NMR (125 MHz, DMSO): δ169.29, 157.42, 149.20, 137.57, 128.80, 128.67, 
128.21, 128.16, 127.99, 70.51, 69.51, 66.24, 56.67, 54.26, 36.06, 32.81, 24.59, 
23.02, 15.49, 11.29.  
[1-13C]-N-Ac-L-Ile-[ring-D4]-L-Tyr 1-13C-N-Ac-L-Ile-[ring-D4]-L-Tyr(OBn)-COOBn 
(1 eq, 46.3 mg, 0.089 mmol) was dissolved in ethanol (2 mL) in a degassed flask 
with 10% wt Pd/C.  The suspension was stirred under a H2 atmosphere at room 
temperature.  The resulting mixture was filtered through a pad of celite and 
concentrated to produce a white solid.  (26.3 mg, 0.078 mmol, 88%) 1H NMR 
 112 
 
(500 MHz, D2O): δ4.71 (q, J = 6Hz, 1H), 3.81-3.71 (m, 1H), 2.96-2.61 (m, 2H), 
2.06 (m, 1H), 2.04 (s, 3H), 1.70 (m, 1H), 1.29 (m, 1H), 1.08 – 1.02 (m, 5H) 13C 
NMR (125 MHz, D2O): δ177.34, 170.92, 170.72, 153.00, 136.77, 58.44, 56.92, 
33.78, 32.21, 23.78, 14.58, 10.32.  
Synthesis of [1-13C]-L-Ile-[ring-D4]-L-Tyr 
N-Cbz-[1-13C]-L-Isoleucine.  [1-13C]-L-isoleucine (1 eq, 32.1 mg, 0.24 mmol) was 
dissolved in ddH2O (75 μL) and NaOH (5M, 50 μL).  The reaction mixture was 
cooled to 0oC while stirring.  Simultaneously, benzyl chloroformate (1.12 eq, 38.5 
μL, 0.27 mmol) and NaOH (2M, 1.12 eq, 135 μL, 0.27 mmol) were added 
drop-wise under argon.  The reaction was allowed to warm to room temperature 
and stirred overnight.  After adjusting the pH of the reaction to 10 (saturated 
aqueous Na2CO3), it was extracted with ether (3 x 10 mL).  The layers were 
separated and the aqueous layer was adjusted to pH 3 and again extracted with 
ether (3 x 10 mL).  The organic layers were combined, dried (MgSO4) and 
concentrated in vacuo to give a clear oil. (50.6 mg, 0.20 mmol, 85%) 1H NMR 
(500 MHz, DMSO): δ7.46 (d, J = 8.5Hz, 1H), 7.37 (s, 5H), 5.02 (s, 2H), 3.89 (q, J 
= 6Hz, 1H), 1.76 (m, 1H), 1.38 (m, 1H), 1.19 (m, 1H), 0.86-0.82 (m, 5H). 13C 
NMR (125 MHz, DMSO): δ173.67, 156.69, 137.42, 128.71, 128.41, 128.17, 
128.11, 126.99, 126.76, 65.78, 63.26, 36.44, 25.02, 15.99, 11.65. 
N-Cbz-[1-13C]-L-Ile-[ring-D4]-L-Tyr(OBn)-COOBn.  N-Cbz-[1-13C]-L-Isoleucine 
(1.05 eq, 25.8 mg, 1.04 mmol), [ring-D4]-L-Tyr(OBn)-COOBn (1 eq, 36.1 mg, 
0.099 mmol) and HOBt (1.1 eq, 14.7 mg, 0.109 mmol) were dissolved in DMF 
(10 mL).  The solution was cooled in an ice-bath and treated with EDC (1.1 eq, 
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20.9 mg, 0.109 mmol) and 2,4,6-Trimethylpyridine (1 eq, 13 μL, 0.099 mmol).  
The mixture was stirred at 0 oC for 1 hr, allowed to warm to room temperature 
and stirred overnight.  The reaction was diluted with EtOAc, washed with 1N HCl 
(3 x 30 mL), 1N NaHCO3 (3 x 30 mL) and brine (3 x 30 mL), dried (MgSO4) and 
concentrated in vacuo to give a white powder. (52.8 mg, 0.089 mmol, 89.6%) 1H 
NMR (500 MHz, DMSO): δ8.15 (d, J = 8.5Hz, 1H), 7.94 (d, J = 8Hz, 1H), 7.70-
7.20 (m, 15H), 5.16-4.99 (m, 6H), 4.97 (q, J = 6Hz, 1H), 3.93-3.89 (m, 1H), 2.97-
2.86 (m, 2H), 2.06 (m, 1H), 1.63 (m, 1H), 1.39 (m, 1H), 1.09-1.02 (m, 5H) 13C 
NMR (125 MHz, DMSO): δ170.81, 166.76, 155.93, 136.72, 135.88, 131.13, 
128.93, 128.88, 128.73, 128.69, 128.48, 128.13, 70.51, 69.51, 55.95, 54.23, 
33.78, 22.21, 15.48, 11.79.  
 [1-13C]-L-Ile-[ring-D4]-L-Tyr N-Cbz-[1-13C]-L-Ile-[ring-D4]-L-Tyr(OBn)-COOBn (1 
eq, 52.8 mg, 0.089 mmol) was dissolved in ethanol (2 mL) in a degassed flask 
with 10% wt Pd/C.  The suspension was stirred under a H2 atmosphere at room 
temperature.  The resulting mixture was filtered through a pad of celite and 
concentrated to produce a white solid.  (23.4 mg, 0.078 mmol, 88%) 1H NMR 
(500 MHz, D2O): δ4.70 (q, J = 6Hz, 1H), 3.81-3.71 (m, 1H), 2.96-2.61 (m, 2H), 
2.06 (m, 1H), 1.70 (m, 1H), 1.30 (m, 1H), 1.08 – 1.02 (m, 5H) 13C NMR (125 
MHz, D2O): δ177.34, 170.92, 153.00, 136.77, 58.44, 56.92, 33.78, 32.21, 23.78, 
14.58, 10.32.  
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Fermentation 
The K-26 producing strain, Astrosporangium hypotensionis, was obtained from 
the Agricultural Research Service (NRRL 12379).  The production protocol of 
Yamato and coworkers was followed with minor modifications.  Seed medium 
consisted of dextrose, 0.1 g/L; Difco soluble starch, 0.1 g/L; Bacto beef extract, 
0.05 g/L; Bacto yeast extract, 0.05 g/L; Bacto tryptone, 0.05 g/L; and CaCO3, 
0.02 g/L dissolved in distilled water and was adjusted to pH 7.2 before 
autoclaving.  Fermentation was initiated by aseptically inoculating one loop of 
mycelia grown on an agar plate into a sterile 50 mL Falcon tube containing 10 
mL seed medium (Phase I).  The Falcon tube was incubated for 10-12 days at 28 
oC in a shaker incubator.  For Phase II, 3 mL of the Phase I seed culture were 
transferred into a 250 mL flask containing 30 mL seed medium.  The Phase II 
seed culture was incubated for 3-4 days at 28 oC in a shaker incubator.  For 
Production, 30 mL of Phase II seed culture was inoculated into a 2800 mL 
Fernbach flask containing 300 mL production medium.  The flask was incubated 
for 5-6 days at 28oC in a shaker incubator.  The production medium consisted of 
Difco soluble starch, 0.4 g/L; soybean meal (Whole Foods), 0.3 g/L; corn steep 
liquor, 0.05 g/L; K2HPO4, 5 mg/L; MgSO4, 2.4 mg/mL; KCl, 3 mg/L and CaCO3, 
0.03 g/L dissolved in distilled water and was adjusted to pH 7.8 before 
autoclaving.   
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Pulse feeding experiments  
1 mM of each precursor (dipeptides and tyramine) was dissolved in 5 mL water 
and administered separately to Phase III culture through a sterile syringe filter in 
every 24 hours for 4 days. 
 
K-26 Extraction 
The production culture was centrifuged.  The cell paste was washed with 20% 
glycerol and the mycelia were frozen in liquid nitrogen for storage at -80 oC, while 
the supernatant was acidified to pH 3.0.  To one liter of supernatant was added 
thirty grams of previously activated Diaion HP-20 resin.  The suspension was 
stirred for 30 minutes.  The resin was filtered and washed with water.  The 
washed resin beads were then stirred in 50% methanol-50% water solution for 10 
minutes.  The suspension was filtered, washed with 50% methanol and 
discarded.  The filtrate was concentrated to 40 mL and neutralized.  The filtrate 
was then additionally concentrated to approximately 1 mL. 
 
K-26 Precursor Incorporation Mass Spectrometry 
General 
  Mass spectrometry was performed using ThermoFinnigan (San Jose, CA) 
TSQ® Quantum triple quadrupole mass spectrometer equipped with a standard 
electrospray ionization source outfitted with a 100-μm I.D. deactivated fused Si 
capillary. Data acquisition and spectral analysis were conducted with Xcalibur™ 
Software, version 1.3, from ThermoFinnigan (San Jose, CA), on a Dell Optiplex 
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GX270 computer running the Microsoft® Windows 2000 operating system. The 
source spray head was oriented at an angle of 90o to the ion transfer tube. 
Nitrogen was used for both the sheath and auxiliary gas. The sheath and 
auxiliary gases were set to 33 and 14 (arbitrary units) respectively. Samples were 
introduced by HPLC. A Surveyor® Autosampler and a Surveyor® MS Pump from 
ThermoFinnigan (San Jose, CA) were used. The injection volume was 10 μL. 
K-26 was separated from co-metabolites using a Jupiter™ minibore 5μm C18 
column (2.0 mm × 15 cm) with a linear water-acetonitrile gradient (ranging from 
95:5 to 5:95 H2O:CH3CN) containing 10 mM ammonium acetate. The flow rate 
was 0.2 mL/min. 
 
Ring-D4-tyramine 
The mass spectrometer was operated in the negative ion mode and the 
electrospray needle was maintained at 4200 V. The ion transfer tube was 
operated at -35V and 350oC. The tube lens voltage was set to -150 V. Source 
CID (offset voltage between skimmer and the first ion guide, Q00) was used at 
15 V. The selected reaction monitoring (SRM) mode was used. Ions were 
collisionally activated with argon at an indicated pressure of 1.4 mT. The mass 
spectral resolution was set to a peak width (full width at half maximum, FWHM) 
of 0.50 u and 0.50 u for precursor and product ions respectively. Mass transitions 
at the specified collision energy (m/z 534216; 35 eV), (m/z 538216; 35 eV) 
and (m/z 538220; 35 eV) were monitored for unenriched K-26, enrichment in 
the central tyrosine and enrichment in AHEP, respectively. The scan width for 
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product ions was 1.000 u and the cycle time for each ion was 0.25 seconds. The 
electron multiplier gain was set to 2 × 106. Data were acquired in profile mode. 
Both a ring-D4-tyramine enriched sample and an unenriched sample were 
scanned. The mass spectral data for the two samples was almost identical, 
indicating no D4 enrichment of K-26. 
 
[1-13C]-N-Ac-L-Ile-[ring-D4]-L-Tyr and [1-13C]-L-Ile-[ring-D4]-L-Tyr. 
 The mass spectrometer was operated in the same manner as for the 
[ring-D4]-tyramine experiments. Transitions (m/z 534216; 35 eV), (m/z 
539216; 35 eV) and (m/z 539220; 35 eV) were monitored for unenriched K-
26, +5 enrichment in N-Ac-Ile-Tyr and +1 enrichment in N-Ac-Ile-Tyr/+4 
enrichment in AHEP. To verify +1 and +4 enrichment, additional transitions were 
monitored.  Transitions (m/z 538216; 35 eV) and (m/z 538220; 35 eV) were 
monitored for +4 enrichment in N-Ac-Ile-Tyr and AHEP, respectively, while 
transitions (m/z 534379; 35 eV), (m/z 535379; 35 eV) and (m/z 535380; 35 
eV) were monitored for unenriched K-26, +1 enrichment in N-Ac-Ile and +1 
enrichment in Tyr-AHEP.  An unenriched sample was used to create theoretical 
curves of ratios of mass isotopomer abundance in K-26 to correct the isotopomer 
distribution of the enriched sample as described previously. 
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Cloning, Expression and Purification of N-Acetyltransferases 
ORF6213 
   N-acetyltransferase ORF6213 was cloned from the genomic DNA of A. 
hypotensionis by PCR using the primers 5'-GCATATGCGGGTCTCGTTCATC-3' 
and 5’-CGTTCGAAGATTAACAAG-3’. The 546 bp PCR product was cloned into 
the vector pCR®2.1-TOPO® using TOPO TA Cloning® Kit (Invitrogen). The gene 
was then subcloned into the expression vector pET28a(+) using NdeI/HindIII 
restriction sites to express N-His6-tagged protein. The resulting plasmid was 
introduced into E.coli BL21(DE3) (Novagen) and the protein was expressed as 
following: in a 2.8-L baffled flask, 2x 500 mL LB medium containing 50 μg/mL 
Kanamycin was inoculated from 2x 5mL overnight cultures made from a fresh 
colony of the above strain and grown at 37°C until OD600 =   ~0.6. IPTG was then 
added (final concentration of 0.5 mM) and the cultures were grown overnight at 
25 °C.  
   The 20.0kD His6-tagged protein was purified as following: the cells were 
pelleted (30 min, 3750 rpm, 4 °C), resuspended in binding buffer (50 mM Tris-
HCl pH 8 containing 300 mM NaCl and 10 mM imidazole) . For cell lysis, DNase I 
(NEB, 0.2 U/mL) was added.  The cells were broken using French pressure cell 
(at 1500 psi). The protein was affinity purified on a HisTrap FF column on an 
ÄKTA chromatography system (GE Healthcare) using binding buffer with linearly 
increasing imidazole concentration (10–500 mM). The pure protein was then 
desalted with a HiTrap Desalting column on the same ÄKTA chromatography 
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system using the assay buffer (20 mM Tris, pH7.5) and stored in aliquots at -80 
°C with 5% glycerol and 1 mM DTT added. 
 
NAT97747 
 NAT97747 was cloned from the genomic DNA of A. hypotensionis by PCR 
using the primers 5'-CATATGCGTTCTGATGTCACCCTGC-3' and 
5’-AAGCTTCAGCCGGCGAGGTCCAC-3’. The 489 bp PCR product was cloned 
into the vector pCR®2.1-TOPO® using TOPO TA Cloning® Kit (Invitrogen). The 
gene was then subcloned into the expression vector pET28a(+) using 
NdeI/HindIII restriction sites to express N-His6-tagged protein. The resulting 
plasmid was introduced into E.coli BL21(DE3) (Novagen) and the ~20kD protein 
was expressed and purified similarly to ORF6213. 
 
N-Acetyltransferase Assay  
Protein fractions (30μL) were incubated with 1 mM AcCoA and 1 mM dK-26 in 20 
mM Tris-HCl pH 8 at a total volume of 90 μL at 30 oC for 4 hours.  After 
incubation, D3-K-26 was added at a 10 nM final concentration. For kinetic 
experiments, dK-26 concentrations ranged from 0.5 mM to 5 mM.  The reaction 
was quenched by addition of an equal volume of methanol and subjected to 
mass spectrometry analysis. 
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N-Acetyltransferase Assay Mass Spectrometry  
Mass spectrometry was performed using a ThermoFinnigan (San Jose, CA) TSQ 
Quantum triple quadrupole mass spectrometer equipped with a standard 
electrospray ionization source outfitted with a 100-μm I.D. deactivated fused Si 
capillary.  The mass spectrometer was operated as above.  A Surveyor 
Autosampler and a Surveyor MS Pump from ThermoFinnigan were used.  The 
injection volume was 10 μL.  Peptides were separated using a Luna minibore 3 
μm C18(2) column (2.0 mm x 5 cm) with an isocratic mobile phase of 90% Buffer 
A, 10% Buffer B (Buffer A: 95% water, 5% acetonitrile 10mM ammonium acetate; 
Buffer B: 5% water, 95% acetonitrile 10 mM ammonium acetate) with a flow rate 
of 0.2 mL/min.  Mass transitions at the specified collision energy (m/z 492216; 
20 eV), (m/z 534216; 20 eV) and (m/z 537216; 35 eV) were monitored for 
dK-26, K-26, and D3-K-26, respectively.  
 
Adenylating Enzyme Purification 
Protein Purification 
Purification was initiated by suspending flash frozen mycelia in general enzyme 
buffer (GEB: 50 mM Tris-HCl pH 7 containing 10% glycerol, 1mM DTT and 0.2 
mM PMSF).  Cells were ruptured at 0 oC using a French pressure  cell.  The 
ruptured cells were centrifuged (16300 x g, 30 min, 4 oC).  The nucleic acids 
were precipitated from the supernatant by adding 5% streptomycin sulfate at 1/5 
volume, stirring at 4 oC for 15 min and centrifuging.  Ammonium sulfate was 
added to the supernatant in portions over 10 min to the desired final saturation 
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and stirred for 1 hr at 4 oC and centrifuged.  The protein pellets were 
resuspended in a minimum volume of GEB and dialyzed overnight versus 3 L of 
GEB at 4 oC. Protein concentrations were measured with Pierce® BCA Protein 
Assay Kit (Thermo Scientific). 
Q-sepharose. The dialysed protein solution was loaded on a Q-sepharose 
(Sigma-Aldrich) column equilibrated with 50 mM Tris, pH 7.5 at 5.0 mL/min using 
a peristaltic pump and eluted using a linear salt gradient 0.0 - 0.5 M NaCl in 50 
mM Tris at pH 7.5. Active fractions were combined and concentrated using an 
Amicon stirred cell. 
Hydrophobic Interaction chromatography. A high salt protein solution was loaded 
on a HiTrap ButylFF column (GE) equilibrated with 50 mM Tris, 1M (NH4)2SO4, 
pH 7.5 using an Akta FPLC at a 1 mL/min flow rate. Proteins were eluted using a 
linear salt gradient 1.0 – 0.0 M (NH4)2SO4 in 50 mM Tris at pH 7.5. 
Size exclusion chromatography. Protein solutions were loaded on a Sephacryl 
S-200 (GE) column equilibrated with GEB at 0.5 mL/min and eluted with GEB. 
DEAE Sepharose. Desalted protein solutions were loaded on a DEAE sepharose 
(GE) column equilibrated with 50 mM Tris, pH 7.2 buffer at 1 mL/min using an 
Akta FPLC. Proteins were eluted using a linear gradient 0.0 - 0.5 M NaCl in 50 
mM Tris at pH 7.2. 
MonoQ. Desalted protein solutions were loaded on MonoQ (GE) column 
equilibrated with 50 mM Tris, pH 7.2 buffer at 1 mL/min using an Akta FPLC. 
Proteins were eluted using a linear gradient 0.0 - 0.5 M NaCl in 50 mM Tris at pH 
7.2. 
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γ-18O4-ATP-PPi Exchange  
Assay Conditions 
In order to avoid precipitation of magnesium pyrophosphate, assay components 
were divided into stock solutions comprising 1) 3 mM amino acids containing 15 
mM PPi in 20 mM Tris pH 7.5, 2) 3 mM γ−18O4-ATP containing 15 mM MgCl2 in 
20 mM Tris pH 7.5 and 3) protein fractions.   Exchange reactions containing 2 μL 
of each component were initiated by the addition of enzyme solution. 6 μL 
reactions contained final concentrations of 5 mM MgCl2, 5 mM PPi, 1 mM γ-18O4-
ATP, 1mM amino acid and 20 mM Tris-HCl pH 7.5.  After incubation at 25 oC, the 
reactions were stopped by the addition of 6 μL 9-aminoacridine in acetone (10 
mg/mL) for MALDI-TOF MS analysis or 6 μL acetone for ESI-LC/MS analysis.  
 
γ-18O4-ATP-PPi Exchange Assay Mass Spectrometry  
MALDI-TOF MS analyses were performed on a Voyager-DE™ STR (Applied 
Biosystems, Inc.) using a nitrogen laser (337 nm).  Prior to analysis, 1 μL of 
analyte/matrix mixture was spotted on to a stainless steel MALDI target.  External 
mass calibration was performed in the reflectron mode using a mixture of γ−18O4-
ATP and γ−16O4-ATP. Mass spectra were acquired in the negative ion mode over 
a range of 450 to 1200 m/z.  Mass spectra for ATP-PPi exchange analysis were 
obtained by averaging 100 consecutive laser shots. Data acquisition and 
quantitative spectral analysis was conducted using Applied Biosystems 
DataExplorer software, version 4.5. 
 123 
 
ESI-LC/MS analyses were performed on a ThermoFinnigan LTQ linear ion trap 
mass spectrometer (Thermo Fisher Scientific, Waltham, MA) equipped with an 
ESI interface in negative ion mode.  Nitrogen was used both for the auxiliary and 
sheath gas.  The auxiliary and sheath gases were set to 20 psi and 36 psi, 
respectively. The following instrumental parameters were used: capillary 
temperature 300 °C; source voltage 4.5 kV; source current 100 μA capillary 
voltage -49.0 V; tube lens -148.30 V; skimmer offset 0.00 V; activation time 
50 ms with an isolation width of 1 m/z.  The sensitivity of the mass spectrometer 
was tuned by infusion of γ-16O4-ATP at a flowrate of 0.1 mL/min.  Samples were 
introduced by a Waters Acquity UPLC system (Waters, Milford, MA) with an 
injection volume of 5 μL. γ-18O4-ATP was separated from contaminating salts on 
a 5 μm Hypercarb column (3 x 50mm, ThermoFisher Scientific) with an isocratic 
method of 82.5% 20 mM ammonium acetate pH 6 containing 0.1% diethylamine 
and 17.5% acetonitrile over 5 minutes with a flow rate of 0.2 mL/min.  
 
tRNA Charging Assay 
Each assay contained 50 mM HEPES-KOH pH 7, 15 mM MgCl2, 15 mM DTT, 5 
mM ATP, 2.5 U Roche total tRNA.  For TyrRS charging, the reaction mixture 
contained 50 μM Tyr with 2 μM L-ring-3,5-3H-Tyr (100 Ci/mmol;  Amersham).  
For IleRS charging, the reaction mixture contained 50 μM Ile with 2.4 μM L-[4,5]-
3H-Ile (40 Ci/mmol; PerkinElmer). To initiate the reaction, 3 μL of MonoQ purified 
protein was added to each reaction.  Reactions were incubated at 37 oC for 25 
min.  The reactions were placed on ice, 25 μL of a 10 mg/mL BSA solution (New 
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England Biosciences) was added followed by 1 mL of cold 10% TCA.  After a 10 
min incubation at 0voC, the solution was filtered through nitrocellulose filters 
(Millipore).  The filters were washed twice with 10% TCA and dissolved in 
FiltronX  (NationalDiagnostics, Atlanta, GA) for analysis.   
 
K-26 analogue production by Sphaerosporangium rubeum  
Culture Conditions 
S. rubeum, was obtained from the Agricultural Research Service (NRRL B-2636).  
The production protocol of K-26 by A. hypotensionis was followed.  Seed medium 
consisted of dextrose, 0.1 g/L; Difco soluble starch, 0.1 g/L; Bacto beef extract, 
0.05 g/L; Bacto yeast extract, 0.05 g/L; Bacto tryptone, 0.05 g/L; and CaCO3, 
0.02 g/L dissolved in distilled water and was adjusted to pH 7.2 before 
autoclaving.  Fermentation was initiated by aseptically inoculating one loop of 
mycelia grown on an agar plate into a sterile 50 mL Falcon tube containing 10 
mL seed medium (Phase I).  The Falcon tube was incubated for 10-12 days at 
28oC in a shaker incubator.  For Phase II, 3 mL of the Phase I seed culture were 
transferred into a 250 mL flask containing 30 mL seed medium.  The Phase II 
seed culture was incubated for 3-4 days at 28 oC in a shaker incubator.  For 
Production, 30 mL of Phase II seed culture was inoculated into a 2800 mL 
Fernbach flask containing 300 mL of production media. Individual production 
cultures, containing one of six possible production media, were incubated for 5-6 
days at 28oC in a shaker incubator.  The production media included K26P: Difco 
soluble starch, 0.4 g/L; soybean meal (Whole Foods), 0.3 g/L; corn steep liquor, 
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0.05 g/L; K2HPO4, 5 mg/L; MgSO4, 2.4 mg/mL; KCl, 3 mg/L and CaCO3, 0.03 g/L 
dissolved in distilled water and adjusted to pH 7.8 before autoclaving; BA: 
Soybean powder, 15 g/L; Glucose, 10 g/L; Difco soluble starch, 10 g/L; NaCl, 3 
g/L; MgSO4*7H2O, 1 g/L; K2HPO4, 1 g/L and 1 mL trace element solution 
(FeSO4*7H2O, 0.01 g/L; MnCl2*4H2O, 0.08 g/L; CuSO4*5H2O, 0.07 g/L; 
ZnSO4*7H2O, 0.02 g/L; 1 drop H2SO4) dissolved in distilled water and adjusted to 
pH 7.2 before autoclaving; EA: lactose, 50 g/L; corn steep solids, 5 g/L; glucose, 
5 g/L; glycerol, 15 g/L; soybean flour, 10 g/L; Bacto peptone, 5 g/L; CaCO3, 3 
g/L; (NH4)2SO4, 2 g/L; FeSO4*7H2O, 0.1 g/L; ZnCl2, 0.1 g/L; MnCl2*4H2O, 0.1 g/L 
and MgSO4*7H2O, 0.5 g/L dissolved in distilled water and adjusted to pH 7.2 
before autoclaving; OA: glucose, 10 g/L; glycerol, 5 g/L; corn steep liquor, 3 g/L; 
beef extract, 3 g/L; malt extract, 3 g/L; yeast extract, 3 g/L and  CaCO3, 2 g/L are 
dissolved in distilled water, adjusted to pH 7.2 and after autoclaving, 0.1 g/L 
thiamine is added; KA: glucose, 10 g/L; corn steep liquor, 10 g/L; soybean 
powder, 10 g/L; glycerol, 5 g/L; dry yeast, 5 g/L and NaCl, 5 g/L are dissolved in 
distilled water, the pH is adjust to 5.7 and 2 g/L CaCO3 is added before 
autoclaving; QB: soluble starch, 5 g/L; glucose, 6 g/L; corn steep liquor, 2.5 g/L; 
Proflo powder, 5 g/L and Proflo oil, 2 mL/L are dissolved in distilled water, the pH 
is adjusted to 7.2 and autoclaved.   
 
K-26 analogue extraction 
The production culture was centrifuged.  The cell paste was discarded and 
the supernatant was acidified to pH 3.0.  To one liter of supernatant was added 
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thirty grams of previously activated Diaion HP-20 resin.  The suspension was 
stirred for 30 minutes.  The resin was filtered and washed with water.  The 
washed resin beads were then stirred in 50% methanol-50% water solution for 10 
minutes.  The suspension was filtered, washed with 50% methanol and 
discarded.  The filtrate was concentrated to 40mL and neutralized.  The filtrate 
was then additionally concentrated to approximately 1mL. 
 
K-26 analogue mass spectrometry 
 Mass spectrometry was performed using FisherScientific (San Jose, CA) 
TSQ® Quantum Access triple quadrupole mass spectrometer equipped with a 
standard electrospray ionization source outfitted with a 100-μm I.D. deactivated 
fused Si capillary. Data acquisition and spectral analysis were conducted with 
Xcalibur™ Software, The source spray head was oriented at an angle of 90o to 
the ion transfer tube. Nitrogen was used for both the sheath and auxiliary gas. 
The sheath and auxiliary gases were set to 33 and 14 (arbitrary units) 
respectively. Samples were introduced by HPLC. A Surveyor® Autosampler and 
a Surveyor® MS Pump from ThermoFinnigan (San Jose, CA) were used. The 
injection volume was 10 μL. K-26 and analogues were separated from co-
metabolites using a Jupiter™ minibore 5μm C18 column (2.0 mm × 15 cm) with a 
linear water-acetonitrile gradient (ranging from 95:5 to 5:95 H2O:CH3CN) 
containing 10 mM ammonium acetate. The flow rate was 0.2 mL/min. 
The mass spectrometer was operated in the negative ion mode and the 
electrospray needle was maintained at 4200 V. The ion transfer tube was 
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operated at -35 V and 350 oC. The tube lens voltage was set to -150 V. Source 
CID (offset voltage between skimmer and the first ion guide, Q00) was used at 
15 V. Precursor ion scanning was used. Ions were collisionally activated with 
argon at an indicated pressure of 1.4 mT and a product ion of m/z 216 was 
chosen.   The mass spectral resolution was set to a peak width (full width at half 
maximum, FWHM) of 0.50 u and 0.50 u for precursor and product ions 
respectively. The scan width for product ions was 1.000 u and the cycle time for 
each ion was 0.25 seconds. The electron multiplier gain was set to 2 × 106. Data 
were acquired in profile mode. Three molecules were identified corresponding to 
K-26, SF2513B and SF2513C in BA and EA media, while only K-26 was 
identified in OA and KA.  Production cultures in QB and K26P media did not 
produce any K-26 or analogues.   
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CHAPTER IV 
 
BIOSYNTHETIC INVESTIGATIONS OF ANTHRAMYCIN 
Introduction 
First described in the early 1940s and structurally characterized in 1963, 
anthramycin is an antitumor and antibiotic peptide natural product.1  Produced by 
the thermophilic actinomycete Streptomyces refuineus sbsp thermotolerans, 
anthramycin is a member of the pyrrolobenzodiazepine (PBD) class of natural 
products2. (Figure IV-1)  These natural products are distinguished by a tricyclic 
ring system formed by an anthranilate (A), a diazepine (B) and a hydropyrrole (C) 
moiety.  Chemical diversity between members of this class is established by the 
varied substitution patterns of the A- and C- rings.  Additional diversity can be 
found within the C-ring including unsaturation at the C2-C3 bond and/or exocyclic 
unsaturated moiety at the C2 position.  The chemical diversity decorating the 
pyrrolobenzodiazepine core modulates the biological potency of these 
compounds, where non-covalent interactions with TA-rich regions in the minor 
groove of double stranded DNA and the irreversible covalent modification of the 
N2-amino group of a neighboring guanine provide the general mechanism for 
both the antitumor and antibacterial activities.3-12 
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Figure 43.  Representative Examples of Bacterial PBDs. These natural products are distinguished by a 
tricyclic ring system formed by an anthranilate (A), a diazepine (B) and a hydropyrrole (C) moiety.  Chemical 
diversity between members of this class is established by the varied substitution patterns of the A- and C- 
rings.    
 
Before our investigations into the biosynthesis of anthramycin, little was 
known about the biosynthesis of PBD natural products.  Previous investigations 
by Hurley and coworkers established the amino acid precursors to both the 
anthranilate and hydropyrrole hemispheres of anthramycin, sibiromycin and 
tomaymycin.2, 13-16  (Figure IV-2) Both hemispheres of anthramycin are derived 
from oxidative ring opening of amino acids: the 3-hydroxyanthranilic acid (HA) 
portion of 4-methyl-3-hydroxyanthranilic acid (MHA) hemisphere is derived from 
tryptophan while the dehydropyrrole hemisphere is derived from tyrosine.  
Methylation of HA and the hydropyrrole moiety are both through methionine.   
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Figure IV-2. Precursor Incorporation Studies of PBDs.  The amino acid precursors of the PBDs have 
been established.  The A-ring of the PBDs is derived from tryptophan, while the C-ring is derived from 
tyrosine.  Methylation of the core structure is methionine dependent. 
 
From these results, Hurley proposed that the MHA portion of anthramycin 
is derived from tryptophan via the kynurenine primary metabolic pathway to give 
HA followed by S-adenosylmethionine (SAM) dependent aromatic C-methylation.  
Additionally, it was proposed that the dehydropyrrole hemisphere is derived from 
tyrosine via a biosynthetic pathway analogous to the biosynthesis of the antibiotic 
lincomycin, which contains a 4-propyl-4,5-dehydroproline moiety, through 
oxidative ring opening of L-DOPA.  Incorporation studies with CH3-labeled 
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methionine into the C-terminal carboxamide of anthramycin and the terminal 
methyl group of the propyl side chain of lincomycin provide additional evidence of 
parallel biosynthesis of anthramycin and lincomycin.   
 
Results 
Biosynthetic hypothesis 
Based on the non-proteinogenic nature of the two amino acids proposed 
in the formation anthramycin, evidenced by the aforementioned isotopic 
incorporation experiments, we proposed an NRPS based biosynthetic hypothesis 
with a proposed domain string of A-T-C-A-T-Re.  The first A-domain of the NRPS 
would activate either HA or MHA and the second A-domain would activate a 
dehydroproline acrylamide moiety for loading on to their respective T-domains.  A 
specialized reductase domain would catalyze the final cyclization to form the 
benzodiazepine ring of anthramycin. Genes homologous to those found with the 
kynurenine primary metabolic pathway will provide the biosynthetic route for HA 
biosynthesis, while those homologous to the biosynthesis 4-propyl-4,5-
dehydroproline moiety of lincomycin will synthesize the dehydroproline moiety 
found in anthramycin. 
 
Genetic Identification of Anthramycin Gene Cluster 
The complete gene cluster for anthramycin biosynthesis was identified by 
our collaborators, Ecopia Biosciences (Thallion Pharmaceuticals), by rapid 
genome-scanning.17 Briefly, a two-tiered genomic DNA library of 1.5-3 kb and 30-
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50 kb fragments was constructed from genomic DNA isolated from S. refuineus 
sbsp thermotolerans.  The short insert library was cloned to give a number of 
genomic sequence tags by sequencing random clones.  These clones were 
analyzed for sequence similarity to verified secondary metabolism gene products 
in the National Center for Biotechnology Information (NCBI) nonredundant 
protein database.  A single genome sequence tag was identified containing 
sequence similarity to the predicted requisite NRPS and used in colony 
hybridization, identifying two cosmids, 024CA and 024CO, generated from the 
large fragment DNA library.  These two overlapping cosmids were sequenced 
providing a putative gene cluster for anthramycin biosynthesis harboring 25 
genes including those consistent with HA biosynthesis, dehydropyrrole moiety 
biosynthesis, a bimodular NRPS terminating with a reductase domain and gene 
candidates consistent with regulation, resistance and transport. (Figure IV-3)  
 
 
Figure IV-344.  The Anthramycin Gene Cluster.  The scientists at Ecopia Biosciences identified the gene 
cluster of anthramycin on two cosmids.  This gene cluster contains an NRPS (red), genes for MHA 
biosynthesis (blue), the dehydroproline acrylamide moiety (green) and regulatory genes (yellow).  Gene 
disruptions of the genes indicated by red boxes were generated.  Anthramycin production was not observed 
in production cultures of the strains with gene disruptions within the cluster. Used with permission.17 
 
To establish the boundaries of this gene cluster and to validate its role in 
anthramycin biosynthesis, a series of PCR-targeted gene replacement 
experiments were performed by Hu et al.17, 18  Developing and using a variation 
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of the λ-RED recombination system, a series of mutants was created including 
disruptions within orfAS10, orf1, orf12, orf19, orf21/orf22, orf23, orf24 and 
orfS11. (Figure IV-3)  Orf1 and orf12 are proposed to be involved in 
dehydropyrrole moiety biosynthesis, while orf19, orf23 and orf24 are proposed to 
be involved in MHA biosynthesis. (Table IV-1) Orf21 and orf22 encode the NRPS 
modules of the biosynthetic pathway with a domain string of A-T (orf21) 
C-A-T-Re (orf22) and orfAS10 and orfS11 are genes flanking the anthramycin 
gene cluster. (Figure IV-3) Production of anthramycin via TLC-bioautography 
(anti-Bacillus) and LC/MS was observed in replacement mutants of orfAS10 and 
orfS11, the genes flanking either side of the anthramycin gene cluster, while 
anthramycin production was not observed in mutants within the proposed gene 
cluster. This verified the identification and isolation of the anthramycin 
biosynthetic gene cluster. 
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Table IV-1.  ORFs Found Within the Anthramycin Gene Cluster 
 
 
Based on genomic analysis, the NRPS within this cluster consists of a 
domain string of A-T-C-A-T-Re with an AT didomain on one module (Orf21) and 
C-A-T-Re (Orf22) on a second module. (Figure IV-4)  To begin studying the 
biochemical mechanisms within anthramycin biosynthesis, we endeavored to 
identify the amino acid substrates of the A-domains within the NRPS.  Based on 
the 8- to 10- amino acid specificity code involved in amino acid discrimination 
within the binding pocket of A-domains, we established no similarity between the 
binding pockets of the A-domains in anthramycin biosynthesis and the specificity 
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code of A-domains with known substrate binding, including that of actinomycin, 
an MHA containing natural product.19  
 
 
Figure IV-4. Proposed Peptide Biosynthesis in Anthramycin.  Based on the structure of anthramycin and 
the identification of a 2 module, 6 domain NRPS, we propose that anthramycin is condensed from two 
hemispheres: MHA and a dehydroproline acrylamide moiety.  An NADH-dependent reductase forms the 
benzodiaxepine ring and releases the peptide from the NRPS. 
  
Proposed MHA biosynthesis 
 Based on homology of primary metabolic genes involved in HA 
biosynthesis, several genes within the anthramycin gene cluster were putatively 
assigned roles in MHA biosynthesis.  Four genes, orf16, orf17, orf20 and orf23, 
show high similarity to genes within the biosynthetic gene cluster of the MHA 
containing natural product actinomycin.  The proposed biosynthetic pathway for 
HA is through oxidative cleavage of L-tryptophan through the kynurenine 
pathway. (Scheme IV-1) Orf17 encodes for a tryptophan-2,3-dioxygenase, 
proposed to catalyse the ring opening of L-tryptophan to give 
N-formylkynurenine.  De-formylation of N-formylkynurenine by orf20, an aryl 
formamidase, provides L-kynurenine which is then hydroxylated at the 3 position 
by orf23, a kynurenine-3-monooxygenase, to give 3-hydroxykynurenine.  Orf16 
catalyzes the loss of alanine from 3-hydroxykynurenine to yield HA.  The 
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presence of a C-methyl substituent at the 4 position of the anthranilate ring, 
shown to be derived from methionine, indicates that a methionine-dependent 
C-methyltransferase should be present within the anthramycin biosynthetic gene 
cluster.  Two genes within the gene cluster have been putatively assigned as 
methyltransferases: orf5 and orf19.  Orf5 shows high sequence similarity to a 
C-methyltransferase within the lincomycin biosynthetic pathway, which has a 
similar dehydroproline subunit, indicating that orf5 is probably involved in the 
biosynthesis of the dehydroproline acrylamide moiety in anthramycin.  Based on 
deductive reasoning, we speculate that Orf19 is the C-methyltransferase 
responsible for appending the methyl group to the 4 position of the anthranilate 
ring.  An additional gene, orf24, is clustered with orf23 and proposed to encode a 
flavin-dependent or amine oxidase, however, the role of Orf24 remains 
speculative. 
 
 
Scheme IV-1.  Possible Biosynthetic Pathway for MHA. Previous precursor incorporation studies coupled 
with the sequence homology of proteins within the anthramycin biosynthetic cassette to proteins involved in 
primary metabolic kynurenine pathway suggest that MHA may be derived from tryptophan through 
kynurenine. 
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Chemical complementation studies to elucidate MHA biosynthesis 
While primary metabolic formation of HA as a precursor to nicotinate-
derived cofactors is through the linear kynurenine pathway from tryptophan, the 
order and substrate specificity of the homologous genes within the anthramycin 
gene cluster may deviate from this paradigm.  In order to establish the timing of 
each step of MHA biosynthesis a series of chemical complementation studies 
was undertaken.  Of particular interest is the timing of C-methylation at the 4 
position.  Isotopic incorporation studies by Hurley and coworkers demonstrated 
incorporation of HA into anthramycin, while MHA was not incorporated.2, 13, 14  
This may be due to lack of transport of MHA across the cell membrane of S. 
refuineus. However, this hypothesis has not been substantiated experimentally.20   
There are two general biosynthetic possibilities for the formation of MHA.  
(Scheme IV-2) In pathway A, C-methylation is proposed to occur subsequent to 
HA formation, via the primary metabolic paradigm.  In this case, C-methylation 
can occur directly after HA formation to give MHA before incorporation into the 
dipeptide or, alternatively, the aryl C-methyl can be inserted during or after 
dipeptide assembly.  In pathway B, methylation occurs at an unknown position in 
the primary anthranilic acid pathway resulting in enzyme substrate divergence 
downstream. 
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Scheme IV-2.  Possible Biosynthetic Pathways for MHA.  Formation of MHA may follow the primary 
metabolic kynurenine pathway to HA followed by C-methylation either before or after incorporation (Pathway 
A). Alternatively, the proteins involved in MHA may function in a sequence divergent from primary 
metabolism if C-methylation occurs before HA formation (Pathway B).  
 
Using S. refuineus strains harboring gene disruptions in orf19, orf23 and 
orf24, genes homologous to those of HA biosynthesis, precursor incorporation 
studies were performed.17  Four possible biosynthetic intermediates: L-
kynurenine, 3-hydroxy- L-kynurenine, HA and MHA were added to growing 
cultures of the S. refuineus mutants to test for their ability to complement the 
three gene-replacement mutants to produce anthramycin.  Butanolic extracts 
prepared from production cultures of the gene-replacement mutants grown were 
subjected to TLC-bioautography and LC/MS analysis.  Both 3-hydroxy- L-
kynurenine and HA were shown to restore benzodiazepine production when 
exogenously supplementing all three mutants, while neither L-kynurenine nor 
MHA were able to complement any of the mutants to produce anthramycin. 
(Table IV-2) 
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Table IV-2.  Results from Chemical Complementation Experiments. Anthramycin = m/z 316; 
desmethylanthramycin = m/z 302 
 
 
For pathway A to be operative and encompass the experimental data, 
transport of L-kynurenine must be unfavorable under our fermentation conditions 
or aryl oxidation may occur earlier in the biosynthesis of HA, slightly diverging 
from primary metabolism.  Additionally, for pathway B to be operative and agree 
with our data, MHA transport must be unfavorable under our fermentation 
conditions, as our data suggests that MHA is not a discrete precursor of 
anthramycin.  As the intermediacy of 3-hydroxy-L-kynurenine is established 
based on its ability to complement anthramycin biosynthesis, we favor pathway 
A.  Chemical complementation of 3-hydroxy-L-kynurenine and HA with the orf23 
and orf24 mutants produced anthramycin. However, chemical complementation 
of the orf19 mutant with these proposed intermediates led to the accumulation of 
a major shunt metabolite, desmethylanthramycin. (Table IV-2) This data indicates 
Orf19 is the C-methyltransferase responsible for insertion of the C-methyl at the 
4 position of MHA, but the aromatic substrate of this enzyme remains elusive.  
These experiments reveal two possible substrates for incorporation into 
anthramycin: HA and MHA. 
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Orf21 amino acid activation  
 As discussed above, an NRPS was identified with in the anthramycin gene 
cluster.  This dimodular NRPS consists of two genes containing six catalytic 
domains in co-linear order on two separate modules orf21 (A-T) and orf22 (C-A-
T-Re). Based on the linear order of the domains within these modules, we 
hypothesized that the first A-domain residing within Orf21 was responsible for 
activating either MHA or HA for incorporation into anthramycin.  Sequence 
analysis of the putative A-domain peptide sequence indicates that it is highly 
divergent from previously studied A-domains.19 (Table IV-3)   
 
Table IV-3.  Specificity Code of the A-domain of Orf21 
 
 
Analysis of the residues in the substrate binding region indicate Asp-235 
(PheA numbering), essential for binding α-amino functionality, is substituted by 
alanine in Orf21. Furthermore, the 8- to 10- amino acid selectivity conferring code 
bears no similarity to previously described A-domains including, notably, 
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actinomycin synthetase ACMS I, which has been reported to activate the MHA 
analog p-toluic acid in the MHA-containing peptide actinomycin.  
To provide direct biochemical evidence for substrate activation of the A-
domain of ORF21, the encoding gene was cloned via polymerase chain reaction 
and ligated into pETDEST-42 for overproduction as a C-terminal His6-tagged 
protein and purified using Ni+2-affinity chromatography.  Purified ORF21 activates 
only MHA and HA, as determined by the mass-based pyrophosphate exchange 
assay, stimulating a 3-fold higher rate of exchange for MHA when the reaction 
mixture is incubated for 30 min at 47oC, the optimal temperature for anthramycin 
production.19 For further characterization of Orf21, apparent kinetic parameters 
were calculated for both MHA and HA. ESI-LC MS analysis yielded apparent KM 
of 33 ± 3 mM and apparent kcat of 130 ± 7 min-1 for MHA and KM of 154 ± 9 mM 
and apparent kcat of 99 ± 2 min-1 for HA.  (Figure IV-5) 
 
 
Figure IV-545.  Amino Acid Concentration Dependence of Orf21.  In order to establish which amino acid 
was the substrate of the A-domain of Orf21, substrate dependent pyrophosphate exchange activity was 
monitored.  MHA stimulated a 3-fold higher exchange rate than HA. 
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Additionally, as an additional layer of substrate discrimination is involved 
in peptide bond formation through the binding pocket of the C-domain of an 
NRPS, MHA loading onto holo-Orf21 was performed.21-24  Using a modified 
version of the T-loading assay, apo-Orf21 was phosphopantetheinylated by Sfp, 
a promiscuous phosphopantetheinyl transferase, and incubated with excess 
MHA.  MHA was successfully loaded onto the T-domain of Orf21.  This indicates 
that MHA is most likely a discrete precursor to anthramycin.  (Figure IV-6) 
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Figure IV-6.  Orf21 T-loading Assay with MHA.  To verify that MHA is the immediate precursor to 
anthramycin, the T-loading assay was performed.  As expected, changes in m/z correlate to the addition of 
the phosphopantetheinyl group (B) and MHA (C). 
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While the apparent kinetic parameters indicate that MHA is a better 
substrate for the A-domain of Orf21, decoupled A-domains are not formally 
catalytic.  Therefore, concentration-response curves of pyrophosphate exchange 
assays cannot be strictly interpreted in terms of Michaelis-Menten steady-state 
kinetics. In order to fully biochemically characterize Orf21 with MHA, we 
comprehensively derived kinetic constants using exchange kinetics based on 
previously described methods. 25-31    
Like tRNA synthetases, ATP-PPi exchange catalyzed by A-domains 
proceeds through an enzyme-bound aminoacyl adenylate intermediate and the 
liberated pyrophosphate product and a modified enzyme form are generated in 
equimolar amounts.32  The binding of amino acid and ATP may proceed by an 
ordered mechanism (mechanism I and II) or by a random mechanism 
(mechanism III) as shown in Figure IV-7.30 Extensive derivations and 
interpretations of these mechanisms have been done by Cleland, Cole and 
Schimmel.27, 28, 30  Briefly, in mechanism I, a product of the enzymatic reaction is 
released before all reactants bind producing two or more stable enzyme forms.  
However, in mechanisms II and III, all reactants bind, the enzymatic reaction 
occurs and all products are released producing only one stable enzyme form.  In 
order to distinguished between these mechanisms, initial velocity is measured as 
a function of the concentration of the variable substrate, while the secondary 
substrate remains constant.28  It is possible to distinguish between possible 
mechanisms when several experiments at different fixed concentrations for the 
secondary substrate are plotted on the same graph.30   For mechanism I, a 
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double-reciprocal plot will yield parallel lines, while mechanisms II and III will 
yield intersecting lines.  For mechanism II, the intersection will occur left of the 
vertical axis when amino acid concentration is varied and on the vertical axis 
when ATP concentration is varied.  For mechanism III, the lines will intersect left 
of the vertical axis when both amino acid and ATP concentration are varied  
 
 
Figure IV-7.  Possible Biochemical Mechanisms for A-domains. A bimolecular enzymatic reaction has 
three possible mechanisms: Bi-Bi Ping-Pong, where substrate A binds, releasing product P to create a 
bound intermediate F, followed by addition of substrate B and subsequent release of product Q to give the 
free enzyme; Ordered Bi-Bi, where substrate A binds, followed by substrate B subsequently, the products P 
and Q are released in a defined order; and Random Bi-Bi where substrates A and B bind in no defined order 
and products P and Q are released at random. 
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The mass based pyrophosphate exchange assay was used following the 
guidelines suggested by Cleland.30 For these experiments, the concentration 
dependence of the exchange rate was investigated by varying the concentrations 
of ATP, pyrophosphate and MHA.  The range of concentrations investigated 
were 0.25 mM - 4 mM ATP, 0.25 mM-4 mM PPi and 10-100 μM MHA.  ATP-PPi 
exchange rates were calculated by standard equations derived by Cole and 
Schimmel28:   
 
[ܧ݋]
ܸ =  
1
݇ܽ݌݌
ቆ 1[ܲܲ] +
߮1
[ܣܣ] +
߮2
[ܣܶܲ] +
߮3
[ܣܣ][ܣܶܲ] +
߮4[ܲܲ]
[ܣܣ][ܣܶܲ] + ߮5ቇ 
  Where: 
߮1 =  
ܭ݁ݍ
ܭܣܶܲ
; ߮2 =  
ܭ݁ݍ
ܭܣܣ
; ߮3 =  ܭ݁ݍ; ߮4 =  
ܭ݁ݍ
ܭܲܲ
; ߮5 =  
1
ܭݔ
 
 
Data was analyzed by plotting V-1 versus [MHA]-1 at different ATP and 
pyrophosphate concentrations and V-1 versus [ATP]-1 at different MHA and 
pyrophosphate concentrations. (Figure IV-8)  
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Figure IV-8.  Equilibrium Kinetics of Orf21 with MHA.  In order to extract equilibrium 
kinetics, pyrophosphate exchange reactions were performed varying ATP and MHA 
concentrations and PPi and MHA concentration.  Plots of this data yield mechanistic 
information, as described in the text.  A: 1/V versus 1/[MHA] for five [ATP] (0.25, 0.50, 1.0, 
2.0 and 4.0 mM from top to bottom). B: 1/V versus 1/[MHA] for five [PP] (0.25, 0.50, 1.0, 
2.0 and 4.0 mM from top to bottom). C: 1/V versus 1/[ATP] for seven [MHA] (10, 25, 40, 
56, 71, 83, 100 μM from bottom to top). C: 1/V versus 1/[PP] for seven [MHA] (10, 25, 40, 
56, 71, 83, 100 μM from bottom to top – only 10, 40, 71 and 100 μM are shown for clarity). 
 
Extrapolations of the primary plots varying both MHA and ATP intersected 
left of the Y-axis.  Based on the work of Cleland and coworkers, this intersection 
pattern is consistent with a random bi-bi mechanism (mechanism III) and is 
distinguished for mechanism I, a non-rapid equilibrium mechanism by lack of 
substrate inhibition by high levels MHA.30  (Figure IV-7)  
To calculate the equilibrium constants, secondary plots were constructed 
plotting the slopes and y-intercepts of the lines versus the changing variable.27  
For instance, in A of Figure IV-8, five different ATP concentrations were used 
over a range of MHA concentrations to yield five lines.  The y-intercepts and 
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slopes of these lines were then plotted against 1/[ATP]. (Figure IV-9) The same 
holds true for the pyrophosphate concentration plots.  
 
Figure IV-9.  Secondary Plots of Orf21 Equilibrium Kinetics.  The y-intercept of the slope replot versus 
1/[ATP] (Left) gives the KMHA constant, while the x-intercept of the y-intercept replot versus 1/[ATP] (Right) 
give the KATP constant.  
 
The y-intercept of the slope plot versus 1/B, where B is [ATP] or [PP] and 
the slope is equal to (Ka/V) where Ka is equal to KAA, while the x-intercept of the y-
intercept replot is equal to -1/Kb.  This yields KAA, KATP and KPP.  To calculate Keq 
and kapp, double reciprocal plots of 1/V and 1/[AA] are created to yield apparent 
kinetic parameters.  These values can then be applied to the equation derived by 
Cole and Schimmel to give Kx, where x is all enzyme forms.28 (Table IV-4) 
 
Table IV-4.  Equilibrium and Kinetic Parameters of Orf21 
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Proposed dehydroproline acrylamide biosynthesis 
 The biosynthetic pathway for the dehydroproline acrylamide hemisphere 
of anthramycin is evidenced by high sequence similarity of a group of genes 
found in the anthramycin gene cluster to those involved in 4-propyl-4,5-
dehydroproline biosynthesis in lincomycin.33  Precursor experiments identified 
tyrosine as the precursor to the dehydropyrrole portion of both natural products 
while methionine dependent methylation is required for formation of the 
acrylamide carbonyl and propyl methyl group of anthramycin and lincomycin, 
respectfully.34-37  While the precise order of biotransformations leading to the 
dehydroproline hemisphere is mostly speculation, the high similarity of orf12 and 
orf13, of the anthramycin gene cluster, to lmbB1 and lmbB2, of the lincomycin 
gene cluster, suggest their involvement in biosynthesis of this moiety. (Table 
IV-1)  LmbB1 and lmbB2 have been demonstrated to convert L-tyrosine to 
L-DOPA and catalyze 2,3-extradiol cleavage via an Fe2+-dependent 
mechanism.38-40  (Scheme IV-3) Based on labeled precursor experiments with 
lincomycin, after oxidative ring opening, glycoxylate (or a chemical equivalent) is 
lost.34  We propose Orf5, a putative methyl transferase with 79% sequence 
identity to lincomycin methyltransferase LmbA, methylates the vinylogous 
dehydroproline intermediate providing a possible branch point for anthramycin 
and lincomycin biosynthesis.  Tautomerization of the imine provides a possible 
substrate for hydroxylation by Orf4 which shows high similarity to cytochrome P-
450 hydroxylases.  Subsequent transformations by Orf3, a putative alcohol 
dehydrogenase; orf2, a putative aldehyde dehydrogenase and orf1, a putative 
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amidotransferase provide a possible route for biosynthesis of the dehydroproline 
acrylamide hemisphere of anthramycin. 
 
 
Scheme IV-3.  Proposed Biosynthetic Pathway for Dehydroproline Acrylamide Hemisphere.  Based 
on the precursor incorporation studies of Hurley et al and the similarity of genes within the anthramycin 
biosynthetic cassette to lincomycin biosynthesis, oxidative ring opening of L-DOPA followed by tailoring 
steps will yield the dehydroproline acrylamide moiety found within anthramycin. 
 
Synthesis of dehydroproline acrylamide Precursor 
 While the biosynthetic precursors of the MHA hemisphere of anthramycin 
were readily available from commercial sources or through simple chemical 
reactions, the biosynthetic precursors of the dehydroproline acrylamide 
hemisphere have to be synthesized.  Recently, Vanderwal and coworkers 
developed a new synthetic route for the synthesis of porothramycins A and B, 
close PBD relatives of anthramycin, through a Zincke pyridinium ring-
opening/ring-closing cascade.41, 42  Modification of this synthetic route could 
possibly provide us with three of the proposed intermediates in the biosynthesis 
of the dehydroproline acrylamide hemisphere of anthramycin.   
 In order to synthesize the proposed dehydroproline acrylamide substrate 
of Orf22, our synthetic route began with Boc-3-(3-pyridyl)-Ala-OH. (Scheme IV-4)  
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After benzyl protection of the carboxylic acid to give Boc-3-(3-pyridyl)-Ala-OBn, 
reflux with 1-chloro-2,4-dinitrobenzene in 1-butanol gave the dinitrobenzyl 
pyridium compound.  Reaction of the dinitrocompound with dimethylamine yields 
the protected aldehyde.  Deprotection of the aldehyde would provide the 
substrate of orf2.  From the protected aldehyde, oxidation to the carboxylic acid 
and subsequent deprotection provides the substrate for orf1.  Reaction of the 
protected aldehyde with manganese oxide in the presence sodium cyanide and 
ammonia provides the protected amide.  Subsequent deprotection provides the 
free amide, yielding the proposed substrate for Orf22 activation. 
 
 
Scheme IV-4.  Proposed Synthesis of Dehydroproline Acrylamide and Intermediates. 
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Discussion 
 Unlike the biosynthetic pathway of K-26, the gene cluster for anthramycin 
was readily identified and verified.  Our collaborators at Ecopia Biosciences (now 
Thallion Pharmaceuticals) were able to isolate the cosmids containing the entire 
biosynthetic cassette for anthramycin biosynthesis by using a two-tiered genetic 
approach. Genetic experiments by Yunfeng Hu in our lab generated a series of 
mutant strains unable to produce anthramycin establishing the role of this gene 
cluster in the biosynthesis.  While the role of a variety of gene products within this 
cluster can be inferred through comparative genetics to similar biosynthetic 
pathways, the biochemical roles of these proteins remained completely 
uninvestigated.  Based on the chemical and genetic similarity of the MHA 
hemisphere of anthramycin to primary metabolic production of HA and the 
dehydroproline acrylamide to the dehydroproline moiety in lincomycin, we were 
able to propose a possible biosynthetic route for both halves.   
For MHA biosynthesis, chemical complementation studies provided us 
with two possible substrates for the NRPS: HA and MHA.  Using the mass-based 
pyrophosphate exchange assay, we were able to show that MHA is most likely 
the immediate precursor to anthramycin through both activation by the A-domain 
of Orf21 and the subsequent loading of the T-domain on the same module.  
Additionally, we determined that the mechanism of an isolated A-domain under 
reversible conditions is random bi-bi.  While we were completing this work, 
Aldrich and coworkers established using a terminal assay that adenylate forming 
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enzymes proceed through a bi-uni-uni-bi ping-pong kinetic mechanism when an 
activated T-domain is present.43 (Figure IV-10)  This corresponds well with the 
mechanism of tRNA synthetases with (bi-uni-uni-bi) and without (bi-bi) tRNA.25  
 
 
Figure IV-10. Proposed Mechanism of A-domain. Recent literature suggests that when a T-domain is 
present, the mechanism of an A-domain is a Bi-Uni-Uni-Bi Ping-Pong mechanism where the amino acid 
binds first, followed by ATP.  The aminoacyl adenylate is formed releasing pyrophosphate.  Subsequently, 
the T-domain binds and is loaded with the amino acid.  The primed T-domain is then released.  Lastly, AMP 
is released from the A-domain. 
 
With the substrate of the MHA hemisphere of anthramycin in hand, we 
turned our investigations to the identification of the substrate of Orf22.  Unlike the 
possible intermediates of the MHA biosynthetic pathway, the substrates 
necessary to investigate the biosynthesis of the dehydroproline acrylamide 
hemisphere were not readily available.  A short synthetic route provides us with 
the amide.  Currently, orf22 is being synthesized by GenScript as cloning of the 
approximately 4kb was unsuccessful.  Once gene synthesis is complete, Orf22 
will be tested for activity with the dehydroproline acrylamide substrate with both 
pyrophosphate exchange and the T-loading assay.  Additionally, investigations of 
the biosynthesis of the amide can be investigated using gene knockouts and 
chemical complementation. Through slight adjustments of the synthetic pathway 
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for the amide, proposed substrates for orf2 (aldehyde) and orf1 (carboxylic acid), 
can be synthesized.   
In addition to assay based biochemical investigations, the small dimodular 
nature of the NRPS within the anthramycin gene cluster provides the perfect 
system for protein crystallography of an entire NRPS. The large size of the total 
NRPS systems limits the ability to crystallize the protein complex successfully.44-
50  Co-expression of Orf21 and Orf22 and in vitro production of anthramycin will 
provide the groundwork for crystallography work.  Future crystallization of the 
NRPS of anthramycin may provide mechanistic insight into the protein-protein 
interactions within these complexes.  Additionally, as more and more genome 
sequences for PBD producers are becoming accessible, it may be possible to 
genetically modify the A-domains to bind non-native substrates to produce novel 
molecules with superior or novel biological activities.51 
After identification and functional determination of the anthramycin gene 
cluster, the bacterial gene clusters of sibiromycin, tomaymycin and 
diazepinomicin/ECO-4601, a novel farnesylated dibenzodiazepinone, were 
identified.52-54  Comparative genomics of the sibiromycin, tomaymycin, 
anthramycin and lincomycin producers provided additional evidence, through 
high similarity and homology of analogous proposed proteins within the cluster, 
that our gene assignments were correct.  Additionally, the 8- to 10- amino acid 
code conferring A-domain specificity of the A-domains activation HA derivatives 
in sibiromycin, tomaymycin, anthramycin and a series of fungal gene clusters 
were extracted.  This information revealed that bacterial substituted anthranilic 
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acid activating A-domains cluster separately from fungal anthranilic acid 
activating A-domains.55  Additionally, all of these β-amino acid have a 
hydrophobic residue, alanine for bacterial A-domains and glycine for fungal A-
domains, at position 235 (GrsA numbering), replacing aspartate. (Table IV-4). 
 
Table IV-4.  Specificity Code of Orf21, SibE and TomA 
 
 
Materials and Methods 
Bacterial Strains and Culture Conditions 
Streptomyces refuineus var. thermotolerans (NRRL 3143) and its derivatives 
were maintained and grown on either ISP4 medium or TSB medium with 
appropriate antibiotics at 37°C. For anthramycin production, S. refuineus and its 
derivatives were cultured in production medium (1% corn starch, 2% peptonized 
milk, and 0.3% yeast extract at pH 7.0) at 47 °C. Bacillus sp. TA (NRRL B-3167) 
was cultured in nutrient agar and used as a test organism for the antibacterial 
activity of S. refuineus and its derivatives. DH10B (Invitrogen) served as host for 
S. refuineus genomic library construction. E. coli BW25113 containing plasmid 
pIJ790 was used for targeted gene disruption in S. refuineus. E. coli ET12567 
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containing the RP4 derivative pUZ8002 was used for intergenetic conjugation 
between E. coli and S. refuineus. E. coli strains were grown in LB medium 
supplemented with appropriate antibiotics for selection of plasmids. 
Preparation of Biosynthetic Intermediates of Anthramycin 
L-kynurenine, 3-hydroxy-L-kynurenine, hydroxyanthranilic acid were purchased 
directly from Sigma Corporation. MHA was prepared by catalytic hydrogenation 
of 4-methyl-3-hydroxy-2-nitrobenzoic acid (Aldrich, Inc.) with Pd/C and H2 at 1 
atm in ethanol. 
 
Chemical Complementation of Anthramycin 
For chemical complementation, corresponding compounds were added directly 
to the production medium at the beginning of fermentation for a final 
concentration of 2 mM. 
 
Production and Detection of Anthramycin 
S. refuineus and its mutant derivatives were cultured in 50 ml seed medium at 
47°C for 24 hr. A 5% inoculum was then added to 50 ml production medium and 
cultured at 47°C for 24 hr. Anthramycin was extracted from the production 
medium with 50 mL butanol. Butanol extracts were concentrated in vacuo and 
redissolved in MeOH. Antibacterial activity of anthramycin was detected by thin-
layer chromatography bioautography.  Anthramycin butanolic extracts (dissolved 
in MeOH) were run on 25DC-Alufolien Kieselgel plates with solvent MeOH:CHCl3 
(1:9); LB agar containing indicator strain Bacillus sp. TA was overlaid on TLC 
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plates and cultured at 37 °C for 20 hr to detect anti-Bacillus activity (evidenced by 
growth inhibition zones) of anthramycin.   
 
Detection of Anthramycin by LC/MS 
Anthramycin production was further confirmed by HPLC/MS. Mass spectrometry 
was performed by using ThermoFinnigan (San Jose, CA) TSQ Quantum triple 
quadrupole mass spectrometer equipped with a standard electrospray ionization 
source outfitted with a 100 mm I.D. deactivated fused Si capillary. The injection 
volume was 10 ml. Anthramycin was separated from co-metabolites by using a 
Jupiter minibore 5 μm C18 column (2.0 mm x 15 cm) with a linear  gradient (0-
100% Buffer B; Buffer A 95% water 5% acetonitrile 10mM ammonium acetate; 
Buffer  B 5% water 95% acetonitrile 10 mM ammonium acetate).  The flow rate 
was 0.2 ml/min. The mass spectrometer was operated in the positive (or 
negative) ion mode, and the electrospray needle was maintained at 4,200 V. The 
ion transfer tube was operated at 35 V and 342 °C (~35 V and 300 °C for 
negative). The tube lens voltage was set to 85 V (~220 V for negative). Source 
CID (offset voltage between skimmer and the first ion guide, Q00) was used at 
15 V. The mass spectrometer was operated in full scan mode with Quad 1. The 
mass spectral resolution was set to a peak width of 0.70 u (full width at half 
maximum, FWHM). Full scan spectra were acquired from m/z 150.0 to 700.0 
(m/z 150.0 to 1200.0 for negative) over 1.0 s. Data were acquired in profile 
mode. The electron multiplier gain was set to 3 x 105. 
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Cloning and Expression of ORF21 
ORF21 was cloned from the Streptomyces refuineus genomic DNA via PCR 
using the primers 5’-CACCATGACAGTACGCAGCACCGCC-3’ and 
5’-GCCTCGGGAACGCTTGGTG-3’ (synthesized by Sigma-Aldrich). The 1.8 kb 
PCR product was cloned into the vector pENTRTM/SD/D-TOPO® using the 
pENTR™ directional TOPO cloning kit (Invitrogen). The gene was subcloned into 
an expression vector pET-DEST42 via LR-recombination using Gateway LR 
Clonase enzyme mix (Invitrogen). The resulting plasmid was introduced into the 
ROSETTA E. coli strain (Novagen). The culture was inoculated (1:100) with an 
overnight culture made from a fresh colony of the above strain and grown at 37 
°C in a 2.8 L baffled flask containing 500 mL LB medium with 100 μg/mL OD600 = 
~ 0.6. IPTG was then added (final concentration of 0.5 mM) and the culture 
grown at °C. The cells were pelleted (30 min, 3750 rpm, 4°C) and resuspended 
in binding buffer (500 mM NaCl, 20 mM NaH2PO4, 20 mM imidazole, pH 7.4). For 
cell lysis, DNase I (NEB, 0.2 U/mL) was added, the cells were disrupted using a 
French pressure cell and filtered through a 0.45-μm filter. The 63 kD protein was 
purified on a HisTrap FF column (GE Healthcare) on an ÄKTA chromatography 
system (GE Healthcare) using binding buffer with linearly increasing imidazole 
concentration (20–500 mM). The pure protein was then desalted with a HiTrap 
Desalting column using 20 mM Tris, pH 7.5 and stored in aliquots at –80°C in 
storage buffer containing 5% glycerol and 1 mM DTT. 
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ATP-PPi Exchange Assay Conditions 
In order to avoid precipitation of magnesium pyrophosphate, assay components 
were divided into stock solutions comprising 1) 3 mM amino acids containing 15 
mM PPi in 20 mM Tris pH 7.5, 2) 3 mM γ−18O4-ATP containing 15mM MgCl2 in 
20 mM Tris pH 7.5 and 3) 600 nM enzyme in 20 mM Tris pH 7.5 containing 5% 
glycerol and 1mM DTT.   Exchange reactions containing 2 μL of each component 
were initiated by the addition of enzyme solution. 6 μL reactions therefore 
contained final concentrations of 5 mM MgCl2, 5 mM PPi, 1 mM γ-18O4-ATP, 1mM 
amino acid and 20 mM Tris-HCl pH 7.5.    After an incubation period (30 min at 
47 oC), the reactions were stopped by the addition of 6 μL acetone for ESI-
LC/MS analysis.  
 
Orf21 Michaelis-Menten Kinetic Parameters 
For Orf21 kinetic measurements, the reactions were performed as described with 
the following modifications: % exchange was measured over a range of MHA 
concentrations (11.5 – 50.0 μM) and HA concentrations (0.115-0.5 mM) and 
rates were measured as single time points at 10 minutes and 15 minutes, 
respectively, corresponding to a maximal % exchange of 15%.  The ‘apparent’ 
substrate dependence parameters, KM and kcat, were calculated from initial 
velocity time curves with varied MHA or HA concentrations using a non-linear 
least square fit to the Michaelis-Menten equation.   
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Orf21 Equilibrium Kinetic Parameters 
For Orf21 kinetic measurements, the reactions were performed as described with 
the following modifications: % exchange was measured over a range of MHA 
concentrations (10 – 100 μM), ATP (0.25 – 4mM) and pyrophosphate (0.25-
4mM) and rates were measured as single time points at 10 minutes. The 
equilibrium constants were derived from double reciprocal plots and secondary 
plots of slopes and intercepts versus substrate concentration. Slope and 
intercept were determined by applying linear regressions using GraphPad Prism. 
 
Mass Spectrometry 
ESI-LC/MS analyses were performed on a ThermoFinnigan LTQ linear ion trap 
mass spectrometer (Thermo Fisher Scientific, Waltham, MA) equipped with an 
ESI interface in negative ion mode.  Nitrogen was used both for the auxiliary and 
sheath gas.  The auxiliary and sheath gases were set to 20 psi and 36 psi, 
respectively. The following instrumental parameters were used: capillary 
temperature 300 °C; source voltage 4.5 kV; source current 100 μA capillary 
voltage -49.0 V; tube lens -148.30 V; skimmer offset 0.00 V; activation time 
50 ms with an isolation width of 1 m/z.  The sensitivity of the mass spectrometer 
was tuned by infusion of γ-16O4-ATP at a flowrate of 0.01 mL/min.  Samples were 
introduced by a Waters Acquity UPLC system (Waters, Milford, MA) with an 
injection volume of 5 μL. γ-18O4-ATP was separated from contaminating salts on 
a 5 μm Hypercarb column (3 x 50 mm, ThermoFisher Scientific) with a isocratic 
method of 82.5% 20 mM ammonium acetate pH 6 containing 0.1% diethylamine 
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and 17.5% acetonitrile over 5 minutes with a flow rate of 0.2 mL/min. A divert 
valve was used for the first two minutes to avoid introducing salts into the source 
and the retention time of ATP species under these conditions was 3 minutes. 
Data acquisition and quantitative spectral analysis was conducted using the 
Thermo-Finnigan Xcaliber software, version 2.0 Sur 1.   
Data Analysis 
Monoisotopic peak area was determined using the respective software for each 
method.  For MALDI-TOFMS analysis, the ratio of the area of γ−16O4-ATP (m/z 
506) to the area of total ATP including unlabeled, partially labeled, fully labeled 
and monosodium-coordinated ions (m/z 506, 508, 510, 512, 514, 528, 530, 532, 
534, 536) was calculated using Microsoft excel and adjusted to reflect actual 
incorporation based on maximum theoretical incorporation to yield percent 
turnover.  For ESI-LC/MS analysis, the ratio of the area of γ−16O4-ATP to the area 
of total ATP including unlabeled, partially labeled, fully labeled, monosodium-
coordinated and sodium acetate adduct ions was calculated using Microsoft 
excel and adjusted to reflect actual incorporation based on maximum theoretical 
incorporation to yield percent turnover.  
 
Sfp cloning and expression 
 Sfp was cloned as previously described.  The resulting plasmid was 
introduced into the ROSETTA E. coli strain (Novagen). The culture was 
inoculated (1:100) with an overnight culture made from a fresh colony of the 
above strain and grown at 37°C in a 2.8 L baffled flask containing 500 mL LB 
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medium with 50 μg/mL kanamycin until OD600 = ~ 0.6 was reached. IPTG was 
then added (final concentration of 1 mM) and the culture grown overnight at 
15°C. The cells were pelleted (30 min, 3750 rpm, 4°C) and resuspended in 
binding buffer (500 mM NaCl, 20 mM NaH2PO4, 20 mM imidazole, pH 7.4). For 
cell lysis, DNase I (NEB, 0.2 U/mL) was added, the cells were disrupted using a 
French pressure  cell and filtered through a 0.45-μm filter. The 26 kD His-tagged 
protein protein was purified on a HisTrap FF column (GE Healthcare) on an 
ÄKTA chromatography system (GE Healthcare) using binding buffer with linearly 
increasing imidazole concentration (20–500 mM). The pure protein was then 
desalted with a HiTrap Desalting column using 20 mM Tris, pH 7.5, flash frozen 
in liquid nitrogen and stored in aliquots at –80°C in storage buffer containing 10% 
glycerol and 1 mM EDTA. 
 
T-loading assay 
 Holo-Orf21 was generated in situ by incubating 25 μM apo-Orf21 with 4 
μM Sfp in the presence of 10 mM MgCl2 and 250 μM Coenzyme-A.  After 1hr, the 
reaction mix was supplemented with 5 mM ATP and 1 mM MHA.  The reaction 
was allowed to incubate for 30 minutes and extraneous salts were removed by 
filtration by centrifugation (10 kD MW cutoff).   
 
Mass Spectrometry for T-domain Loading 
ESI-LC/MS analyses were performed on a ThermoFinnigan LTQ linear ion trap 
mass spectrometer (Thermo Fisher Scientific, Waltham, MA) equipped with an 
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ESI interface in positive ion mode.  Nitrogen was used both for the auxiliary and 
sheath gas.  The auxiliary and sheath gases were set to 20 psi and 36 psi, 
respectively. The following instrumental parameters were used: capillary 
temperature 300 °C; source voltage 4.5 kV; source current 100 μA capillary 
voltage -49.0 V; tube lens -148.30 V; skimmer offset 0.00 V; activation time 
50 ms with an isolation width of 1 m/z.  Samples were introduced by a Waters 
Acquity UPLC system (Waters, Milford, MA) with an injection volume of 10 μL. 
Orf21 was separated from contaminating co-purified proteins on a Waters 
Acquity UPLC HEB C8 column (1.0 x 150 mm, 1.7 μm), with a gradient method 
of 30% B to 100% B over 10 minutes (Buffer A: 80% water, 10% acetonitrile, 
10% isopropanol, 2% acetic acid, 0.2% trifluoroacetic acid; Buffer B: 20% water, 
70% acetonitrile, 10% isopropanol, 2% acetic acid, 0.2% trifluoroacetic acid).  
Data acquisition and spectral analysis was conducted using the BioMass 
software.   
 
Synthesis of dehydroproline acrylamide derivatives 
Boc-3-(3-pyridyl)-Ala-OBn  
To a stirred solution of Boc-3-(3-pyridyl)-Ala-OH (1 eq, 300 mg, 1.13 mmol) in 
anhydrous CH2Cl2 (10 mL) was added DMAP (0.1 eq, 13.8 mg, .113 mmol) and 
benzyl alcohol (4 eq, 468 μL, 4.52 mmol).  The reaction was cooled to 0oC and 
EDC (3 eq, 238 mg, 3.39 mmol) was added..  After stirring for 5 minutes, the 
reaction was allowed to warm to room temperature and stirred overnight. The 
reaction mixture was washed with HCl (0.5N, 2 x 30 mL) followed by saturated 
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NaHCO3 (3 x 30 mL) and dried (MgSO4).  The solvent was removed in vacuo to 
yield the crude ether.  The ether was purified by column chromotography (100% 
DCM followed by 4% MeOH in DCM) to give the pure compound (230 mg, 0.64 
mmol, 57%) 1H NMR (400 MHz, CDCl3): δ8.49 (s, 1H), 8.36 (s, 1H), 7.58-7.33 
(m, 4H), 7.16 (s, 1H), 5.07 (d, 2H), 4.98 (s, 1H), 4.55 (s, 1H), 3.19 (m, 1H), 3.06 
(m, 1H), 1.44 (s, 9H). 13C NMR (100 MHz, CDCl3): δ171.10, 150.52, 148.37, 
136.70, 134.86, 131.52, 128.60, 123.26, 67.33, 54.03, 35.48, 28.18. 
 
Boc-3-(3-(2,4-dintrophenyl)pyridinium)-Ala-OBn  
To a solution of Boc-3-(3-pyridyl)-Ala-OBn (1 eq, 50 mg, 0.14 mmol) in 1-butanol 
(0.1 mL) was added 1-chloro-2,4-dinitrobenzene (1 eq, 28.4 mg, 0.14 mmol).  
The resulting solution was heated to 100oC and stirred for 3 hours.  After cooling 
to room temperature, the solvent was removed in vacuo.  The material was 
purified by silica gel chromatography (20% MeOH in DCM). (36.8 mg, 0.066 
mmol ,47%) 1H NMR (400 MHz, DMSO): δ9.400 (s, 1H), 9.322 (m, 1H), 9.129 (s, 
1H), 8.989 (m, 1H), 8.840 (m, 1H), 8.380 (m, 2H), 7.368 (s, 5H), 5.168 (s, 1H), 
4.540 (broad s, 1H), 3.223 (m, 2H) 1.326 (s, 9H) 13C NMR (100 MHz, DMSO): 
δ162.70, 155.85, 149.57, 143.29, 138.95, 136.11, 132.26, 130.50, 128.79, 
128.52, 128.24, 121.92, 79.10, 66.72, 53.99, 36.17, 33.42, 31.15, 28.42. 
 
Boc-(3-oxoprop-1-enyl)-2,3-dihydropyrrole-COOBn 
To a solution of Boc-3-(3-(2,4-dinitrophenyl)pyridinium)-Ala-OBn (1 eq, 10 mg, 
0.018mmol) in ethanol (100 proof, 471μL) at 50oC, under anhydrous condtions, 
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was added dimethylamine (2.0 M in MeOH, 5 eq, 45μL, 0.09 mmol) and the 
reaction vessel was opened to atmosphere.  The solution was heated to 65oC 
and stirred until the solution turned from a deep maroon to red.  The mixture was 
allowed to cool to room temperature and concentrated in vacuo.  Water was 
added and the aqueous solution was extracted with DCM (3 x 10 mL).  The 
organic extracts were combined, washed with brine (3 x 30 mL), dried (MgSO4), 
filtered and concentrated in vacuo.  The aldehyde was purified via silica gel 
chromatography (1:1 EtOAc:hexanes) followed by phenylhexyl LC/MS. (2.95 mg, 
0.008 mmol, 46%). 
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CHAPTER V 
 
FUTURE DIRECTIONS 
 
 The research described within the previous chapters has been the initial 
biosynthetic investigations of both K-26 and anthramycin.  As these are initial and 
preliminary investigations more experiments will be required to fully investigate 
the biosynthesis of these molecules.  Herein, I will discuss possible paths of 
investigations. 
K-26 
Unfortunately, we have not been able to unambiguously identify the gene 
cluster responsible for K-26 biosynthesis by genomic analysis.  The ability to 
identify the proteins responsible for K-26 biosynthesis is limited by the production 
levels of K-26.  Correspondingly, the proteins involved in K-26 are presumably 
also produced at extremely low levels.  In order to isolate the proteins 
responsible for K-26 biosynthesis, it will be necessary to increase the production 
level of K-26 in A. hypotensionis or identify another producer with higher 
production levels.  To increase production levels of K-26 in A. hypotensionis or 
another producer, mutagenesis experiments were begun by Dr. Jaeheon Lee 
using UV-radiation. 
The results of the aforementioned experiments seem to indicate that the 
N-acetyltransferase responsible for acetylating dK-26 may not be clustered with 
the rest of the genes responsible for K-26 biosynthesis.  Speculatively, if 
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acetylation is occurring through off-target activity of a variety of 
N-acetyltransferases and peptide bond formation is through a promiscuous 
ligase, the only genes required for K-26 biosynthesis are those encoding the 
proteins responsible for AHEP formation.  This lack of clustering may limit the 
handles available for investigation to AHEP formation.  Additional difficulties lie in 
the lack of information about the precursors of AHEP.  From the stable-labeled 
precursor incorporation experiments, we know that AHEP is derived from 
L-tyrosine and AHEP is a discrete precursor of K-26, however, during the 
previously described experiments, at no time was dK-26 or K-26 formation 
observed when L-isoleucine, L-tyrosine and AHEP were incubated with cell-free 
extract of A. hypotensionis.  In order to identify the proteins required for AHEP 
formation, the phosphate source and additional cofactors will have to be 
identified.  Additionally, as AHEP formation is expected to be the rate limiting 
step in K-26 biosynthesis, it will be necessary to develop an extremely sensitive 
assay for AHEP formation. 
In order to do this, the best course of action would require the ability to 
detect AHEP in cell-free extract.  AHEP is easily separated from contaminating 
salts by using a Hypercarb column.  Initial experiments with a full gradient from 
0% acetonitrile (100% 20 mM ammonium acetate pH 6 with 0.1% TEA) to 100 % 
acetonitrile will provide a good starting point for method development for LC/MS 
methodology.  After development of the LC/MS method, limit of detection 
experiments must be undertaken.  In order to detect AHEP formation, it will be 
necessary to detect 0.01% AHEP in cell-free extract.  To do this, L-tyrosine, a 
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phosphate mixture and AHEP of known concentrations are added to cell-free 
extract.  The cell-free extract is heated to 95 oC, to denature the proteins and 
centrifuged to remove the precipitated proteins.  The supernatant would then be 
subjected to LC/MS analysis.  After limits of detection experiments in both full 
scan and SRM (AHEP readily fragments, verify by product ion scanning), initial 
cell-free experiments can be undertaken.  If AHEP still cannot be detected, it may 
be necessary to further concentrate AHEP from the cell-free extract.  To do this, I 
would recommend using either a gallium or zinc affinity column, similar to nickel 
affinity used for protein purification.  This would necessitate identifying another 
compound capable of eluting AHEP from the column.   
Once the detection method is developed and AHEP can be detected in 
cell-free extraction, identification of the phosphate source can be undertaken.  As 
mentioned in Chapter III, L-tyrosine is an immediate precursor of AHEP, 
however, the phosphate source and any required cofactors remain unidentified.  
Under cell-free extract conditions, no supplementation with phosphate or 
cofactors should be necessary to observe conversion of tyrosine to AHEP.  To 
identify the phosphate source, incubation of a co-factor mix containing all 
possible co-factors with a mix of possible phosphate sources should increase the 
conversion of tyrosine to AHEP in cell-free extract.  After formation of AHEP can 
be detected, process of elimination can first identify the phosphate source and 
then identify the required co-factors. 
Subsequent to the identification of the phosphate source and the required 
co-factors, protein fractionation can be performed using traditional bioactivity 
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guided fractionation similar to that discussed in Chapter III.  Proteomics analysis 
of active protein fractions will identify prospective proteins.  Hopefully, possible 
candidates can be eliminated by correlating identified prospective proteins with a 
gene cluster with either an NRPS or genes for isoleucine or tyrosine 
biosynthesis. 
Complementary to reverse genetic experiments, heterologous expression 
of A-domains within prospective K-26 gene clusters has been undertaken.  While 
this has been an ongoing route to identify of the K-26 biosynthetic cassette, 
expression of K-26 A-domains in heterologous hosts has proved to be 
challenging, limiting the success of this endeavor.  Recent reports have indicated 
that small MbtH-like proteins often found near or within NRPS gene clusters may 
play a role in increasing the solubility and expression levels of A-domains when 
co-expressed in heterologous hosts.  Future work co-expressing these proteins 
may help to identify and/or eliminate prospective gene clusters involved in K-26 
biosynthesis. 
 
Anthramycin 
Unlike the possible intermediates of the MHA biosynthetic pathway, the 
substrates necessary to investigate the biosynthesis of the dehydroproline 
acrylamide hemisphere are not readily available.  A short synthetic route will 
provide the amide.  Our synthetic route also yields the aldehyde and acid 
proposed biosynthetic precursors of the amide (See Chapter IV).  Orf22 was 
successfully synthesized by GenScript and is currently subcloned into the 
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pET28(a) vector.  Successful expression and purification of Orf22 will allow for 
biochemical characterization of the enzyme.  Orf22 will be tested for activity with 
the dehydroproline acrylamide substrate with both pyrophosphate exchange and 
the T-loading assay.  Additionally, investigations of the biosynthesis of the amide 
can be investigated using gene knockouts and chemical complementation. 
Through slight adjustments of the synthetic pathway for the amide, proposed 
substrates for orf2 (aldehyde) and orf1 (carboxylic acid), can be synthesized.   
In addition to assay based biochemical investigations, the small dimodular 
nature of the NRPS within the anthramycin gene cluster provides the perfect 
system for protein crystallography of an entire NRPS. The large size of the total 
NRPS systems limits the ability to crystallize the protein complex successfully.1-7  
Co-expression of Orf21 and Orf22 and in vitro production of anthramycin will 
provide the groundwork for crystallography work.  Future crystallization of the 
NRPS of anthramycin may provide mechanistic insight into the protein-protein 
interactions within these complexes.  Additionally, as more and more genome 
sequences for PBD producers are becoming accessible, it may be possible to 
genetically modify the A-domains to bind non-native substrates to produce novel 
molecules with superior or novel biological activities.8
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